ARRANGEMENT AGREEMENT May 11, 2017

any effect, changes, developments or events generally affecting the pharmaceutical industry or any other industry in which the Company or a Company Subsidiary operates;

any change, effect or event arising from or out of any change or proposed changes in (or change in or new interpretation of) Laws (including any Laws in respect to Taxes), IFRS or regulatory accounting requirements;

the failure of the Company or the Company Subsidiaries to meet any internal or published projections, forecast or estimates of, or guidance related to, revenues, earnings, cash flows or other financial metrics before, on or after the date of this Agreement (provided, however, that the facts, circumstances, changes, effects, occurrences or events giving rise to or contributing to the failure (other than those in clauses (a) to (b) above or (d) to (k) below) may constitute, in and of itself and themselves, a Material Adverse Change or Material Adverse Effect and may be taken into consideration when determining whether a Material Adverse Effect has occurred);

any change in general economic, political, business, regulatory, or market conditions or in national or global financial or capital markets;

any changes or developments in relation to currency exchange or interest rates;

any earthquake, hurricane, tornado, tsunami, flood or other natural disaster or outbreak or escalation of hostilities or acts of war (whether or not declared) or act of terrorism;

the announcement of this Agreement or the pendency of the transactions contemplated hereby;

any changes in the trading price or trading volumes of the Common Shares or any suspension of trading in securities generally on the TSX or NASDAQ, or any credit rating downgrade, negative outlook, watch or similar event relating to the Company (provided, however, that the causes underlying such changes (other than those in clauses (a) to (g) above or (i) to (k) below) may constitute, in and of itself and themselves, a Material Adverse Change or Material Adverse Effect and may be taken into consideration when determining whether a Material Adverse Effect has occurred);

any actions taken (or omitted to be taken) by the Company or the Company Subsidiaries at the request or with the prior written consent of the Purchaser;

any fact, circumstance, change, effect, occurrence or event reasonably foreseeable from the information expressly disclosed in the Company Disclosure Letter; or

any action that is required pursuant to this Agreement;

Headings, etc. The provision of a Table of Contents, the division of this Agreement into Articles and Sections and the insertion of headings are for convenient reference only and do not affect the construction or interpretation of this Agreement.

Currency. All references to dollars or to $ are references to Canadian dollars, unless specified otherwise.

Gender and Number. Any reference to gender includes all genders. Words importing the singular number only include the plural and vice versa.

Certain Phrases, etc. The words (i) “including”, “includes” and “include” mean “including (or includes or include) without limitation,” (ii) “the aggregate of”, “the total of”, “the sum of”, or a phrase of similar meaning means “the aggregate (or total or sum), without duplication, of,” and (iii) unless stated otherwise, “Article”, “Section”, and “Schedule” followed by a number or letter mean and refer to the specified Article or Section of or Schedule to this Agreement.

Capitalized Terms. All capitalized terms used in any Schedule or in the Company Disclosure Letter have the meanings ascribed to them in this Agreement unless otherwise defined therein.

Knowledge. Where any representation, warranty, or other provision of this Agreement is expressly qualified, activated, or otherwise limited by or involving the knowledge of the Company, it is deemed to refer to the actual knowledge of the Company’s Chief Executive Officer, Chief Financial Officer, VP & Head of European Operations, VP, Regulatory and Quality Affairs, and VP, Business Development, each in their capacity of officers or employees of the Company and not in their personal capacity or any other capacity, and is deemed to include the knowledge that each would have if reasonable and diligent inquiries had been made. Where any representation, warranty, or other provision of this Agreement is expressly qualified, activated, or otherwise limited by or involving the knowledge of the Purchaser, it is deemed to refer to the actual knowledge of ▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇▇▇▇▇▇▇ Bath, each in their capacity of officers of the Purchaser and not in their personal capacity or any other capacity, and is deemed to include the knowledge that each would have if reasonable and diligent inquiries had been made.

Definition of “made available”. The term “made available” means (i) copies of the subject materials were included in the Data Room or in the Company Public Disclosure Record prior to the date of this Agreement, (ii) copies of the subject materials were provided to the Purchaser or its representatives, or (iii) the subject material was listed and described in reasonable detail in the Company Disclosure Letter and copies were provided to the Purchaser by the Company if requested.

Accounting Terms. All accounting terms are to be interpreted in accordance with IFRS and all determinations of an accounting nature in respect of the Company required to be made shall be made in a manner consistent with IFRS.

Statutes. Any reference to a statute refers to such statute, or successor thereto, and all rules, resolutions and regulations made under it, or its successor, respectively, as it or its successor, or they, may have been or may from time to time be amended or re-enacted, unless stated otherwise.

Computation of Time. A period of time is to be computed as beginning on the day following the event that began the period and ending at 4:30 p.m. on the last day of the period, if the last day of the period is a Business Day, or at 4:30 p.m. on the next Business Day if the last day of the period is not a Business Day. If the date on which any action is required or permitted to be taken under this Agreement by a Person is not a Business Day, such action shall be required or permitted to be taken on the next succeeding day which is a Business Day.

Time References. References to time are to local time, Toronto, Ontario.

Subsidiaries. To the extent any covenants or agreements relate, directly or indirectly, to a Subsidiary of the Company, each such provision shall be construed as a covenant by the Company to cause (to the fullest extent to which it is legally capable) such Subsidiary to perform the required action.

Schedules. The schedules attached to this Agreement form an integral part of this Agreement for all purposes of it.

for the classes of persons to whom notice is to be provided in respect of the Arrangement and the Company Meeting and for the manner in which such notice is to be provided;

that the required level of approval for the Arrangement Resolution shall be: (a) at least two-thirds of the vote cast on the Arrangement Resolution by the Common Shareholders, voting as a single class, present or in person or represented by proxy at the Company Meeting, with each Common Shareholder being entitled to one vote for each Common Share held by such holder and (b) if required, a majority of the votes cast attached to the Common Shares held by Common Shareholders present in person or represented by proxy at the Company Meeting excluding, for this purpose, votes attached to the Common Shares that are required to be excluded pursuant to MI 61-101, and that these shall be the only requisite approvals required by the Common Shareholders;

that, in all other respects, the terms, restrictions and conditions of the Company’s Constating Documents, including quorum requirements and all other matters, shall apply in respect of the Company Meeting;

for the grant of the Dissent Rights to those Common Shareholders who are registered Common Shareholders as contemplated in the Plan of Arrangement;

for the notice requirements with respect to the presentation of the application to the Court for the Final Order;

that the Company Meeting may be adjourned or postponed from time to time by the Company in accordance with the terms of this Agreement without the need for additional approval of the Court;

that the record date for the Common Shareholders entitled to notice of and to vote at the Company Meeting will not change in respect of any adjournment(s) or postponements of the Company Meeting, unless required by Law; and

for such other matters as the Purchaser may reasonably require, subject to obtaining the prior consent of the Company, such consent not to be unreasonably withheld or delayed.

convene and conduct the Company Meeting in accordance with the Interim Order, the Company’s Constating Documents and Law as soon as reasonably practicable (and in any event before July 14, 2017) and shall not adjourn, postpone or cancel (or propose the adjournment, postponement or cancellation of) the Company Meeting without the prior written consent of the Purchaser, except as required or permitted under Section 4.9(3) or Section 5.4(5), or as required for quorum purposes (in which case, the Company Meeting, shall be adjourned and not cancelled) or as required by Law or by a Governmental Entity;

subject to the terms of this Agreement and compliance by the directors and officers of the Company with their fiduciary duties, use its commercially reasonable efforts to solicit proxies in favour of the approval of the Arrangement Resolution and against any resolution submitted by any Person that is inconsistent with the Arrangement Resolution and the completion of any of the transactions contemplated by this Agreement, including, if so requested by the Purchaser, acting reasonably, using proxy solicitation services firms (at the expense of the Purchaser) and cooperating with any Persons engaged by the Purchaser to solicit proxies in favour of the approval of the Arrangement Resolution;

provide the Purchaser with copies of or access to information regarding the Company Meeting generated by any proxy solicitation services firm, as requested from time to time by the Purchaser;

fix the record date for notice and voting of the Company Meeting as soon as practicable following the date hereof, in consultation with the Purchaser, and give notice to the Purchaser of the Company Meeting and allow the Purchaser’s representatives and legal counsel to attend the Company Meeting;

at the reasonable request of the Purchaser from time to time, the Company shall provide the Purchaser with lists (in written and/or electronic form), which lists shall include names, addresses and holdings of (i) the registered Common Shareholders, (ii) all Persons holding Company Options and/or Company PSUs and (iii) non-objecting beneficial Common Shareholders. The Purchaser may from time to time request the Company to require, and the Company shall require, that the registrar and transfer agent for the Common Shares furnish the Purchaser with additional information and other assistance as the Purchaser may reasonably request;

promptly advise the Purchaser, at such times as the Purchaser may reasonably request and at least daily on each of the last five Business Days prior to the date of the Company Meeting, as to the aggregate tally of the proxies received by the Company in respect of the Arrangement Resolution;

promptly advise the Purchaser of any material communication (written or oral) from or claims brought by (or threatened to be brought by) any Person in opposition to the Arrangement and/or purported exercise or withdrawal of Dissent Rights by Common Shareholders, and the Company shall not settle or compromise or agree to settle or compromise any such Dissent Rights without the prior written consent of the Purchaser, not to be unreasonably withheld, conditioned or delayed, and the Company shall provide the Purchaser with an opportunity to review and comment on any written communication sent by or on behalf of the Company to any Common Shareholder exercising or purporting to exercise Dissent Rights and provide the Purchaser with a copy of any such written communication; and

not change the record date for the Common Shareholders entitled to vote at the Company Meeting in connection with any adjournment or postponement of the Company Meeting unless required by Law, or as otherwise contemplated under the terms of this Agreement or agreed to in writing by the Parties.

The Company shall, so as to permit the Company Meeting to be held by the date specified in Section 2.3: (i) subject to the Purchaser’s compliance with Section 2.4(4), prepare and complete, in consultation with the Purchaser, the Company Circular, together with any other documents required by Law in connection with the Company Meeting; (ii) reasonably promptly after obtaining the Interim Order, use commercially reasonable efforts to cause the Company Circular and such other documents to be filed and disseminated to each Common Shareholder, holder of Company Options, holder of Company PSUs and other Person as required by the Interim Order and Law; and (iii) to the extent required by Law, as promptly as reasonably practicable, use commercially reasonable efforts to prepare, file and disseminate to the Company Shareholders and other Persons as required by the Interim Order and Law any supplement or amendment to the Company Circular (after the Purchaser has had a reasonable opportunity to review and comment thereon) if the Company shall become aware of any event which requires such action at any time prior to the Company Meeting.

The Company shall ensure that the Company Circular complies in all material respects with the Interim Order and Law, does not contain any Misrepresentation (other than with respect to any information furnished by the Purchaser or their affiliates whether pursuant to Section 2.4(2) or otherwise) and provides the Common Shareholders with sufficient information to permit them to form a reasoned judgement concerning the matters to be placed before the Company Meeting. Without limiting the generality of the foregoing but subject to the terms of this Agreement and the compliance by the directors and officers of the Company with their fiduciary duties, the Company Circular must include: (i) a copy of the Fairness Opinions, (ii) the Board Recommendation, and (iii) a statement that each of the Supporting Shareholders has signed a Voting Agreement, pursuant to which, and subject to the terms thereof, they have agreed to, among other things, to vote all of such Person’s Common Shares (including any Common Shares issued upon the exercise of any Company Options or settlement of Company PSUs) in favour of the Arrangement Resolution.

The Company shall give the Purchaser and its legal counsel a reasonable opportunity to review and comment on drafts of the Company Circular and other related documents, and shall give reasonable consideration to any comments made by the Purchaser and its counsel, and agrees that all information relating solely to the Purchaser included in the Company Circular must be in form and content satisfactory to the Purchaser, acting reasonably.

The Purchaser shall provide on a timely basis all necessary information concerning the Purchaser and its affiliates that is required by Law to be included by the Company in the Company Circular, or other related documents, to the Company in writing, and shall use its best efforts to ensure that such information does not contain any Misrepresentation. The Purchaser shall indemnify and save harmless the Company and its affiliates and its respective Representatives from and against any and all liabilities, claims demands, losses, costs, damages and expenses (excluding any loss of profits or consequential damages) to which they may be subject or may suffer, in any way caused by, or arising, directly or indirectly, from or in consequence of:

any Misrepresentation or alleged Misrepresentation in the Company Circular; and

any Order made by, or Proceeding brought, conducted or heard by or before, any Securities Authority or other Governmental Entity based upon any Misrepresentation in the Company Circular;

except that the Purchaser shall only be liable in any such case to the extent that any such liabilities, claims, demands, losses, costs, damages and expenses arise out of or are based solely upon any Misrepresentation contained in information included in the Company Circular provided by the Purchaser in writing for inclusion in the Company Circular.

The Company and the Purchaser will promptly notify each other if any of them becomes aware that the Company Circular contains a Misrepresentation, or otherwise requires an amendment or supplement. The Parties shall cooperate in the preparation of any such amendment or supplement as required or appropriate, and the Company shall promptly mail, file or otherwise publicly disseminate any such amendment or supplement to those Persons to whom the Company Circular was sent pursuant to Section 2.4(1) and, if required by the Court or by Law, file the same with the Securities Authorities or any other Governmental Entity as required.

Subject to the terms of this Agreement, pursuant to the Arrangement:

each outstanding Company PSU that is outstanding at the Effective Time, whether vested or unvested shall, without any act or formality on the part of the holder thereof, be disposed of and surrendered by the holder thereof, to the Company in exchange for a cash payment (net of any applicable withholdings) equal to (A) the number of Common Shares subject to the Company PSU immediately prior to the Effective Time, multiplied by (B) the Consideration;

each outstanding Company Option that is outstanding at the Effective Time, whether vested or un-vested shall, without any act or formality on the part of the holder thereof, be disposed of and surrendered by the holder thereof, to the Company in exchange for a cash payment (net of any applicable withholdings) equal to the Consideration multiplied by the number of Common Shares subject to the Company Option less the applicable exercise price, if such amount is greater than zero.

The Parties acknowledge that no deduction will be claimed by the Company or any Person not dealing at arm’s length with the Company in respect of any payment made to a holder of Company Options in respect of the Company Options pursuant to the Arrangement who is a resident of Canada or who is employed in Canada (all for purposes of the Tax Act), in computing the Company’s, or any Person not dealing at arm’s length with the Company, taxable income under the Tax Act and the Purchaser shall cause the Company to: (i) where applicable, make an election pursuant to subsection 110(1.1) of the Tax Act in respect of the cash payments made in exchange for the surrender of Company Options; and (ii) provide evidence in writing of such election to holders of Company Options, it being understood that holders of Company Options will be entitled to claim any deductions available to such persons pursuant to the Tax Act in respect of the calculation of any benefit arising from the surrender of Company Options.

The Arrangement shall be effective at the Effective Time on the Effective Date. The completion of the Arrangement shall occur no later than on the third Business Day (or on such other day as the Parties shall agree upon in writing) after the satisfaction or, where not prohibited, the waiver by the applicable Party in whose favour the condition is, of the conditions set forth in Article 6 (excluding the condition in Section 6.3(3) and conditions that, by their terms, cannot be satisfied until the Effective Date) (the “Filing Date”), and subject to the satisfaction or, where not prohibited, the waiver of the applicable Party or Parties in whose favour the condition is, of those conditions as of the Effective Date, the Arrangement Filings shall be filed on (and not prior to) the Filing Date by the Company with the Registrar pursuant to section 292(a) of the BCBCA and the Arrangement shall become effective on the date the Arrangement Filings are so filed. On the Filing Date each of the Parties shall use its reasonable best efforts to, as soon as practicable, satisfy all conditions in Article 6 that by their terms cannot be satisfied until the Effective Date, subject to its rights to waive any such condition in accordance with Article 6.

From and after the Effective Time, the Plan of Arrangement will have all of the effects provided by Law, including the BCBCA. The Company agrees to amend the Plan of Arrangement at any time prior to the Effective Time in accordance with Section 8.1 to include such other terms determined to be necessary or desirable by the Purchaser, provided that the Plan of Arrangement shall not be amended in any manner which (a) has the effect of reducing the Consideration, (b) which is otherwise prejudicial to the Common Shareholders or other parties to be bound by the Plan of Arrangement or (c) is inconsistent with the provisions of this Agreement or the Interim Order or the Final Order.

The closing of the Arrangement will take place at the offices of Torys LLP, 79 Wellington St. W., 30th Floor, TD ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇ at 8:00 a.m. on the Effective Date, or at such other time and place as may be agreed to by the Parties.

Except as set forth in the correspondingly numbered paragraph of the Company Disclosure Letter (or any other paragraph of the Company Disclosure Letter to the extent that the relevance of the disclosure set out or the document referenced therein is reasonably apparent), the Company represents and warrants to the Purchaser as set forth in Schedule C and acknowledges and agrees that the Purchaser is relying upon such representations and warranties in connection with the entering into of this Agreement.

Except for the representations and warranties set forth in this Agreement, neither the Company nor any other Person makes or has made any representation or warranty, express or implied, either written or oral, at law or in equity, on behalf of or in respect of the Company.

The representations and warranties of the Company contained in this Agreement shall not survive the completion of the Arrangement and shall expire and be terminated at the Effective Time.

The Purchaser represents and warrants to the Company as set forth in Schedule D and acknowledges and agrees that the Company is relying upon such representations and warranties in connection with the entering into of this Agreement.

Except for the representations and warranties set forth in this Agreement, neither the Purchaser nor any other Person makes or has made any representation or warranty, express or implied, either written or oral, at law or in equity, on behalf of or in respect of the Purchaser.

The representations and warranties of the Purchaser contained in this Agreement shall not survive the completion of the Arrangement and shall expire and be terminated at the Effective Time.

The Company covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, except:

with the prior written consent of the Purchaser (which consent shall not be unreasonably withheld, delayed or conditioned);

as required or permitted by this Agreement;

as required by any Contract or Law, including the rules or requirements of the TSX or NASDAQ;

as expressly disclosed in Section 4.1(1) of the Company Disclosure Letter; or

as expressly contemplated by a Pre-Acquisition Reorganization,

the Company shall, and shall cause each of the Company Subsidiaries to, conduct its business in the Ordinary Course and in accordance with Law, and the Company shall use commercially reasonable efforts to maintain and preserve its and the Company Subsidiaries’ business organization, Company Assets, employees, goodwill and business relationships with customers, suppliers, distributors, licensors, partners and other Persons with which the Company or any Company Subsidiary has business relations and to perform and comply with all of its obligations under the Material Contracts.

Without limiting the generality of Section 4.1(1), the Company covenants and agrees that, during the period from the date of this Agreement until the earlier of the Effective Time and the time that this Agreement is terminated in accordance with its terms, that except in the situations or circumstances contemplated by Section 4.1(1)(a) to (1)(d), neither the Company nor any Company Subsidiary shall, directly or indirectly:

amend its articles of incorporation, articles of amalgamation, by-laws or similar organizational documents;

split, combine, reclassify or amend the terms of any securities of the Company or of any Company Subsidiary;

redeem, repurchase, or otherwise acquire or offer to redeem, repurchase or otherwise acquire any shares of capital stock of the Company or any Company Subsidiary except for (i) the acquisition of shares of capital stock of any wholly-owned Subsidiary of the Company by the Company or by any other wholly-owned Subsidiary of the Company; or (ii) pursuant to the cashless exercise of Company Options or the forfeiture or withholding of Taxes with respect to Company Options or Company PSUs;

other than (i) pursuant to the exercise of Company Options in accordance with the terms of the Company Option Plan, (ii) the issuance of Common Shares pursuant to the terms of outstanding Company PSUs in accordance with the terms of the PSU Plan, or (iii) the grant of Company Options or Company PSUs in the Ordinary Course consistent with past practice (including in connection with the hiring of new Company Employees), issue, grant, deliver, sell, pledge or otherwise encumber, or authorize the issuance, grant, delivery, sale, pledge or other encumbrance of any shares of capital stock, securities, any options, warrants or similar rights exercisable or exchangeable for or convertible into such capital stock, of the Company or any Company Subsidiary;

acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, in one transaction or in a series of related transactions, any assets, securities, properties, interests or businesses if such acquisition would have a cost, on a per transaction or series of related transactions basis, in excess of $2 million and subject to a maximum of $4 million for all such transactions;

reorganize, amalgamate or merge the Company or any Company Subsidiary (except as permitted by paragraph (e) immediately above or in connection with any Pre-Acquisition Reorganization);

reduce the stated capital of the shares of the Company or any Company Subsidiary;

adopt a plan of liquidation or resolutions providing for the liquidation or dissolution of the Company or any Company Subsidiary (except as permitted by paragraph (e) immediately above or in connection with any Pre-Acquisition Reorganization);

other than Permitted Liens, sell, pledge, lease, dispose of, surrender, lose the right to use, mortgage, license, encumber or otherwise dispose of or transfer any assets of the Company or of any Company Subsidiary or any interest in any assets of the Company or the Company Subsidiaries having a value greater than $2 million in the aggregate or constituting Intellectual Property that is material to the business of the Company and the Company Subsidiaries taken as a whole, other than accounts receivable, production and inventory sold in the Ordinary Course;

make any capital expenditure or commitment to do so which individually, or in the aggregate, exceeds $2 million;

make, rescind or change any material Tax election or designation, settle or compromise any material Tax claim, assessment, reassessment or liability, file any amended Tax Return, enter into any material agreement with a Governmental Entity with respect to Taxes, consent to the extension or waiver of the limitation period applicable to any material Tax matter or materially amend or change any of its methods of reporting income, deductions or accounting for income Tax purposes except as may be required by Law;

in the case of the Company and any Company Subsidiary that is resident in Canada for purposes of the Tax Act make any "investment" (within the meaning of subsection 212.3(10) of the Tax Act) in a corporation that is not resident in Canada;

except in connection with customary internal cash management activities, make, in one transaction or in a series of related transactions, any loans, advances or capital contributions to, or investments in, or assume, guarantee or otherwise become liable with respect to the liabilities of, any Person, other than the Company or any wholly-owned Subsidiary of the Company in an amount on a per transaction or series of related transactions basis in excess of $2 million individually and $4 million in the aggregate;

prepay any long-term indebtedness before its scheduled maturity or increase, create, incur, assume or otherwise become liable, in one transaction or in a series of related transactions, with respect to any indebtedness for borrowed money or guarantees thereof in an amount, on a per transaction or series of related transactions basis, in excess of $2 million other than (i) indebtedness owing by one wholly-owned Company Subsidiary to the Company or another wholly-owned Subsidiary of the Company or of the Company to another wholly-owned Company Subsidiary, (ii) in connection with the refinancing or renegotiation of the terms of indebtedness outstanding on the date hereof in the Ordinary Course (provided such refinanced or renegotiated indebtedness is prepayable at the Effective Time with any additional premium, penalty or other incremental costs (including breakage costs) attributable to such refinancing or renegotiation not to exceed $100,000), (iii) in connection with advances in the Ordinary Course under the Company’s or any Company Subsidiary’s existing credit facilities, (iv) indebtedness entered into in the Ordinary Course or in connection with the Arrangement, (v) in the Ordinary Course enter into any interest rate, currency, equity or commodity swaps, ▇▇▇▇▇▇, derivatives, forward sales contracts or similar financial instruments, or (vi) with the prior written consent of the Purchaser, not to be unreasonably withheld, conditioned or delayed;

other than as disclosed in Section 4.1(2)(o) of the Company Disclosure Letter, make any bonus or profit sharing distribution or similar payment of any kind;

make any material change in the Company’s methods of accounting, except as required by concurrent changes in IFRS;

except in the Ordinary Course or as disclosed in Section 4.1(2)(q) of the Company Disclosure Letter, grant any general increase in the rate of wages, salaries, bonuses or other remuneration of any Company Employees or increase the benefits under Employee Plans;

except in the Ordinary Course or as required by Law or as disclosed in Section 4.1(2)(r) of the Company Disclosure Letter, (i) increase any severance, retention, change of control or termination pay to (or amend any existing arrangement with) any member of senior management or any director or officer of the Company or any Company Subsidiary; (ii) increase the benefits payable under any existing severance or termination pay policies with any member of senior management or any director or officer of the Company or any Company Subsidiary; (iii) increase the compensation or benefits payable under any employment agreements with any member of senior management or any director or officer of the Company or any Company Subsidiary; (iv) enter into any employment, deferred compensation or other similar agreement (or amend any such existing agreement) with any member of senior management or any officer or director of the Company or any Company Subsidiary; or (v) increase compensation, bonus levels or other benefits or perquisites payable to any member of senior management or any director or officer of the Company or any Company Subsidiary;

except as required by Law or as disclosed in Section 4.1(2)(s) of the Company Disclosure Letter, adopt any new Employee Plan or any material amendment or modification of an existing Employee Plan;

except as required by Law, enter into any Collective Agreement or other Contract with a labour organization representing any of the Company Employees;

remove any auditor or director or terminate any senior officer or other senior Company Employee absent removal for cause;

grant an exclusive license or otherwise transfer any Intellectual Property or exclusive rights in or in respect thereto that is material to the Company and the Company Subsidiaries taken as a whole, other than in the Ordinary Course or to the Company Subsidiaries;

commence, waive, release, assign, or settle any litigation, proceedings or governmental investigations in excess of an amount of $2 million individually, or $4 million in the aggregate or which would reasonably be expected to impede, prevent or delay the consummation of the transactions contemplated by this Agreement;

except in the Ordinary Course, amend or modify in any material respect or terminate or waive any material right under any Material Contract or enter into any contract or agreement that would be a Material Contract if in effect on the date hereof;

except as contemplated in Section 4.10 or as would not individually or in the aggregate be material to the Company, amend, modify, terminate, cancel or let lapse any material insurance (or re-insurance) policy of the Company or any Company Subsidiary in effect on the date of this Agreement, unless simultaneously with such termination, cancellation or lapse, replacement policies underwritten by insurance and re-insurance companies of nationally recognized standing providing coverage equal to or greater than the coverage under the terminated, cancelled or lapsed policies for substantially similar premiums are in full force and effect;

abandon or fail to diligently pursue any application for any material Authorizations, or take any action, or fail to take any action, that results in the termination of any material Authorizations; or

authorize, agree, resolve or otherwise commit, whether or not in writing, to do any of the foregoing.

The Company shall, and shall cause the Company Subsidiaries to, perform all obligations required or desirable to be performed by the Company or any Company Subsidiary under this Agreement, reasonably cooperate with the Purchaser in connection therewith, and do all such other acts and things as may be necessary or desirable in order to consummate and make effective, as soon as reasonably practicable, the transactions contemplated by this Agreement and, without limiting the generality of the foregoing, the Company shall, and shall cause the Company Subsidiaries, as applicable, to:

use commercially reasonable efforts to satisfy all conditions precedent in this Agreement and take all steps set forth in the Interim Order and Final Order applicable to it and comply promptly with all requirements imposed by Law on it or the Company Subsidiaries with respect to this Agreement or the Arrangement;

use commercially reasonable efforts to obtain and maintain all third party or other consents, waivers, permits, exemptions, orders, approvals, agreements, amendments or confirmations that are (i) necessary or advisable to be obtained under the Material Contracts in connection with the Arrangement or (ii) required in order to maintain the Material Contracts in full force and effect following completion of the Arrangement, in each case, on terms that are satisfactory to the Purchaser, acting reasonably but without paying or committing itself or the Purchaser to pay any consideration or incurring any liability or obligation that is not conditioned on consummation of the Arrangement;

use commercially reasonable efforts to effect all necessary registrations, filings and submissions of information required by Governmental Entities from the Company and the Company Subsidiaries relating to the Arrangement;

use commercially reasonable efforts, upon reasonable consultation with the Purchaser, to oppose, lift or rescind any injunction, restraining or other order, decree or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Arrangement and defend, or cause to be defended, any proceedings to which it is a party or brought against it or its directors or officers challenging the Arrangement or this Agreement; provided, that neither the Company nor any of the Company Subsidiaries shall consent to the entry of a judgement or settlement with respect to such proceeding without the prior consent of the Purchaser;

not take any action, or refrain from taking any commercially reasonable action, or permit any action to be taken or not taken, which is inconsistent with this Agreement or which would reasonably be expected to prevent, materially delay, or otherwise impede the consummation of the Arrangement or the other transactions contemplated by this Agreement; and

subject to obtaining an irrevocable and complete release and discharge from all claims and potential claims in respect of the period prior to the Effective Time in favour of each member of the Board and the boards of directors of the Company Subsidiaries and confirmation that insurance coverage is maintained as required by Section 4.10, use commercially reasonable efforts to assist in effecting the resignations of each member of the Board and the board of directors of each of the Company’s Subsidiaries (in each case to the extent requested by Purchaser and in a form satisfactory to the Purchaser), and causing them to be replaced by Persons nominated by Purchaser effective as of the Effective Time.

The Company shall promptly notify the Purchaser in writing of:

any Material Adverse Effect or any fact or state of facts, circumstance, change, effect, occurrence or event which could reasonably be expected to have a Material Adverse Effect subject to compliance with applicable competition or anti-trust Laws;

any notice or other communication from any Person alleging that the consent (or waiver, permit, exemption, order, approval, agreement, amendment or confirmation) of such Person (or another Person) is or may be required in connection with this Agreement or the Arrangement;

any notice or other communication from any material supplier, marketing partner, customer, distributor, licensor or reseller to the effect that such supplier, marketing partner, customer, distributor, licensor or reseller is terminating, may terminate or is otherwise materially adversely modifying or may materially adversely modify its relationship with the Company or any Company Subsidiaries as a result of this Agreement or the Arrangement;

any notice or other communication from any Governmental Entity in connection with the Agreement (and, subject to Law, the Company shall contemporaneously provide a copy of such written notice or communication to the Purchaser); or

any material filing, actions, suits, claims, investigations or proceedings commenced or, to its knowledge, threatened against, relating to or involving or otherwise affecting the Company, the Company Subsidiaries, or the Company Assets.

The Purchaser shall perform all obligations required or desirable to be performed by it under this Agreement, reasonably cooperate with the Company in connection therewith, and do all such other commercially reasonable acts and things as may be necessary or desirable in order to consummate and make effective, as soon as reasonably practicable, the transactions contemplated by this Agreement and, without limiting the generality of the foregoing, the Purchaser shall:

use commercially reasonable efforts to satisfy all conditions precedent in this Agreement and take all steps set forth in the Interim Order and Final Order applicable to it and comply promptly with all requirements imposed by Law on it with respect to this Agreement or the Arrangement;

use commercially reasonable efforts to cooperate with the Company in its efforts to obtain and maintain all third party or other consents, waivers, permits, exemptions, orders, approvals, agreements, amendments or confirmations that are, in the Purchaser’s discretion, acting reasonably, (i) necessary or advisable to be obtained under the Material Contracts in connection with the Arrangement or (ii) required in order to maintain the Material Contracts in full force and effect following completion of the Arrangement, in each case, on terms that are satisfactory to the Purchaser, acting reasonably;

use commercially reasonable efforts to effect all necessary registrations, filings and submissions of information required by Governmental Entities from it relating to the Arrangement;

use commercially reasonable efforts, upon reasonable consultation with the Company, to oppose, lift or rescind any injunction, restraining or other order, decree or ruling seeking to restrain, enjoin or otherwise prohibit or adversely affect the consummation of the Arrangement and defend, or cause to be defended, any proceedings to which it is a party or brought against it or its directors or officers challenging the Arrangement or this Agreement provided that the Purchaser shall not consent to the entry of a judgment or settlement with respect to such proceeding without the prior consent of the Company; and

not take any action, or fail to take any commercially reasonable action, that is inconsistent with or that would reasonably be expected to prevent, materially delay or otherwise impede the consummation of the Arrangement or the transactions contemplated by this Agreement.

The Purchaser shall promptly notify the Company in writing of any material filings, actions, suits, claims, investigations or proceedings commenced or, to its knowledge, threatened against, relating to or involving the Purchaser that relate to this Agreement or the Arrangement.

As soon as reasonably practicable after the date hereof, the Purchaser shall make all notifications, filings, applications and submissions with Governmental Entities required or advisable, and shall use its commercially reasonable efforts to obtain and maintain the Regulatory Approvals.

The Parties shall cooperate with one another in connection with obtaining the Regulatory Approvals including providing or submitting on a timely basis, and as promptly as reasonably practicable, all documentation and information that is required, or in the opinion of the Company or the Purchaser, acting reasonably, advisable in connection with obtaining the Regulatory Approvals and use their reasonable best efforts to ensure that such information does not contain a Misrepresentation; provided, however, that nothing in this provision shall require a Party to provide information that is not in its possession or not otherwise reasonably available to it. For greater certainty, the Parties agree that from the date hereof until the earlier of: (i) the Effective Time; and (ii) this Agreement having been terminated in accordance with its terms, each of them shall use reasonable best efforts to promptly and expeditiously take all steps to permit the Effective Date to occur at the earliest reasonable possible date and in any event prior to the Outside Date and to obtain the Regulatory Approvals as soon as reasonably practicable.

The Parties shall (i) cooperate with one another, and use commercially reasonable efforts to keep one another fully informed as to the status of and the processes and proceedings relating to obtaining the Regulatory Approvals and shall promptly notify each other of any communication from any Governmental Entity in respect of the Arrangement or this Agreement, (ii) provide timely input into any submissions, applications, notifications, filings or written representations to any Governmental Entity in connection with obtaining the Regulatory Approvals and (iii) respond as promptly as practicable to any requests for information from a Governmental Entity in connection with obtaining a Regulatory Approval. The Company shall not make any submissions, applications, notifications, filings or representations to any Governmental Entity relating to any Regulatory Approval or in respect of the Arrangement or this Agreement without the prior approval of the Purchaser or unless required under Law (provided that, if required under Law, the Company shall use commercially reasonable efforts to give the Purchaser a reasonable opportunity to review and comment on any such submissions, applications, notifications, filings, or representations). Submissions, applications, notifications, filings or written representations to any Governmental Entity may be redacted as necessary before sharing with the other Party to address reasonable attorney-client or other privilege or confidentiality concerns, provided that a Party must provide external legal counsel to the other Party non-redacted versions of drafts and final submissions, applications, notifications, filings or written representations to any Governmental Entity on the basis that the redacted information will not be shared with its clients.

Each Party shall promptly notify the other Party if it becomes aware that any (i) application, filing, document or other submission for a Regulatory Approval contains a Misrepresentation, or (ii) any Regulatory Approval contains, reflects or was obtained following the submission of any application, filing, document or other submission containing a Misrepresentation, such that an amendment or supplement may be necessary or advisable. In such case, the Parties will cooperate in the preparation, filing and dissemination, as applicable, of any such amendment or supplement.

If applicable and commercially reasonable, the Parties shall request that the Regulatory Approvals be processed by the applicable Governmental Entity on an expedited basis and, to the extent that a public hearing is held, the Parties shall request the earliest reasonably possible hearing date for the consideration of the Regulatory Approvals. Related thereto, the Parties, as applicable, shall promptly notify any Governmental Entity that is responsible for issuing a Regulatory Approval that it is prepared to meet, by telephone or in person at the Governmental Entity’s offices, with a view to obtaining the Regulatory Approvals as soon as reasonably practicable.

If any objections are asserted with respect to the transactions contemplated by this Agreement under any Law, or if any proceeding is instituted or threatened by any Governmental Entity challenging or which could lead to a challenge of any of the transactions contemplated by this Agreement as not in compliance with Law or as not satisfying any applicable legal text under a Law necessary to obtain the Regulatory Approvals, the Parties shall use their reasonable best efforts consistent with the terms of this Agreement to resolve such proceeding so as to allow the Effective Time to occur on or prior to the Outside Date.

The Purchaser shall be responsible for and shall pay any and all filing fees and Taxes payable to a Governmental Entity including by any of the Company or the Company Subsidiaries in connection with any application, notification or filing in respect of any of the Regulatory Approvals.

The Purchaser shall use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary to arrange and obtain the Financing described in the Financing Documents on the terms and conditions described therein by no later than the Closing and shall not, without the consent of the Company, permit any amendment or modification to be made to, or any waiver of any provision or remedy under the Financing Documents, in each case that, would reasonably be expected to (I) reduce the aggregate amount of the Financing (including by changing the amount of fees to be paid or original issue discount of the Financing) unless from (x) alternative financing to the extent required or permitted pursuant to this Section 4.5, or (y) satisfactory evidence has been provided to the Company that there has been a corresponding increase in equity financing pursuant to adequate binding arrangements enforceable by the Company and/or cash from the Purchaser, (II) prevent the availability of the Financing on Closing or (III) make the funding of the Financing (or satisfaction of the conditions to obtaining the Financing) materially less likely to occur or (IV) materially impair, delay or prevent the consummation of the transactions contemplated by this Agreement. Without limiting the foregoing, the Purchaser shall use its reasonable best efforts (i) to maintain in effect the Financing Documents until the consummation of the transactions contemplated hereby, and

At the request of the Purchaser, the Company shall use its reasonable best efforts to, and shall cause the Company Subsidiaries to use their reasonable best efforts to, deliver all notices and take all other actions reasonably requested by the Purchaser (including without limitation, assisting with obtaining customary payout and Lien release letters) to facilitate the termination of any commitments under the Existing Credit Agreement, the repayment in full of all obligations then outstanding thereunder (using funds provided by the Purchaser) and assisting with obtaining the release of all Liens in connection therewith on the Effective Date (such termination, repayment and release, the “Credit Agreement Termination”); provided, that in no event shall this Section 4.5 require the Company or any of the Company Subsidiaries to cause such Credit Agreement Termination unless the Closing shall have occurred and Purchaser shall have provided to the Company with all necessary funds payable in connection with the Credit Agreement Termination.

The Company shall provide, and shall use its reasonable best efforts to cause its Representatives to provide, all reasonable and timely cooperation in connection with the arrangement of the Purchaser’s Financing as may be reasonably requested by the Purchaser, including, if requested by the Purchaser: (a) participating in meetings (including meetings with rating agencies), and due diligence sessions; (b) cooperating with the Purchaser in connection with applications to obtain such consents, approvals or authorizations which may be reasonably necessary or desirable in connection with such Financing; (c) at least three (3) Business Days prior to the Closing providing all customary documentation and other information about the Company and the Company Subsidiaries requested in connection with the Financing and required under applicable “know your customer” and anti-money-laundering rules and regulations; and (d) taking all corporate actions, to be effective at the Effective Time, requested by the Purchaser that are necessary or customary to permit the consummation of such Financing and to permit the proceeds thereof, together with the cash of the Company and the Company Subsidiaries, to be made available to the Purchaser on the Effective Date to consummate the transactions contemplated hereby.

Notwithstanding Section 4.5(3), the obligations of the Company and its Representatives under such Section 4.5(3) are subject to: (i) any such requests being made on reasonable notice; (ii) none of such requests being reasonably expected to conflict with, or contrary to, in any material respect, any Law or a binding obligation under any Contract; (iii) none of such requests requiring the Company to pay any commitment, consent or other similar fee, or incurring, assuming or being subject to any liability or obligation, or entering into any binding agreement or commitment (other than an agreement or commitment contingent upon the occurrence of the Closing), in each case, in connection with any such Financing prior to the Closing; (iv) none of such requests unduly interfering with the conduct of the business of the Company in the Ordinary Course; or (v) none of the forgoing requiring the directors, officers or employees of the Company to take any action in any capacity other than as a director, officer or employee of the Company.

The Company on behalf of itself and the Company Subsidiaries hereby consents to the use of their logos in connection with the Financing; provided, that such logos are used solely in a manner that is not intended to or reasonably likely to harm or disparage the Company or the Company Subsidiaries, or the reputation or goodwill of the Company or the Company Subsidiaries.

The Purchaser agrees to indemnify the Company, the Company Subsidiaries and their respective Representatives from and against any and all liabilities, losses, damages, claims, costs, expenses, interest, awards, judgements and penalties (collectively, “Losses”) suffered or incurred by any of them in connection with a request by the Purchaser made under Section 4.5(2) or Section 4.5(3) (including with respect to any Losses arising out of any information provided by the Company and relating to the Company and the Company Subsidiaries except to the extent arising from any fraud, gross negligence or willful misconduct by the Company). The Purchaser will promptly upon request by the Company from time to time reimburse the Company for all reasonable out- of-pocket costs (including legal fees) incurred by the Company or the Company Subsidiaries and their respective Representatives in connection with any of the foregoing.

From the date hereof until the earlier of the Effective Time and the termination of this Agreement in accordance with its terms, subject to Law and the terms of any existing Contracts, the Company shall, and shall cause the Company Subsidiaries to, make available to the Purchaser and its representatives: (a) all data and information of the Company and the Company Subsidiaries’ senior personnel as the Purchaser may reasonably request (including continuing access to the Data Room) for the purpose of facilitating integration business planning; and (b) reasonable access to during normal business hours to their premises, Company Assets, Material Contracts, auditors and advisors; provided, in each case, that: (i) the Purchaser provides the Company with reasonable notice of any request under this Section 4.6(1); (ii) other than with respect to the Data Room, access to any materials contemplated in this Section 4.6(1) shall be provided during the Company’s normal business hours only; and (iii) the Company’s compliance with any request under this Section 4.6(1) shall not unduly interfere with the conduct of the Company’s business, or any obligation of confidentiality owed by the Company to a third party. Neither the Purchaser nor any of its representatives will contact directors, officers, employees, customers, suppliers or other business partners of the Company or of the Company Subsidiaries in connection with the transactions contemplated by this Agreement except after receiving the prior written consent of the Company.

Investigations made by or on behalf of the Purchaser, whether under this Section 4.6 or otherwise, will not mitigate, waive, diminish the scope of, or otherwise affect any representation or warranty made by the Company in this Agreement.

For greater certainty, the Purchaser and its affiliates shall treat, and shall cause their respective representatives to treat, all information furnished to the Purchaser and/or any of their respective affiliates, representatives in connection with the transactions contemplated by this Agreement or pursuant to the terms of this Agreement, in accordance with the terms of the Confidentiality Agreement. The Purchaser acknowledges that the Confidentiality Agreement continues to apply and that any information provided by or on behalf of the Company under this Agreement shall be subject to the terms of the Confidentiality Agreement.

For the purposes of this section, “Transferred Information” means the personal information as defined in Privacy Law (namely, information about an identifiable individual other than their business contact information when used or disclosed for the purpose of contacting such individual in that individual’s capacity as an employee or an official of an organization and for no other purpose) to be disclosed or conveyed to one Party or any of its representatives or agents (a “Recipient”) by or on behalf of another Party (a “Disclosing Party”) as a result of or in conjunction with the transactions contemplated herein, and includes all such personal information disclosed to the Recipient prior to or following the execution of this Agreement.

Each Disclosing Party acknowledges and confirms that the disclosure of Transferred Information is necessary for the purposes of determining if the Parties shall proceed with the transactions contemplated herein, and that the disclosure of Transferred Information relates solely to the carrying on of the business and the completion of the transactions contemplated herein.

Each Disclosing Party covenants and agrees to, upon request, use commercially reasonable efforts to advise the Recipient of all documented purposes for which the Transferred Information was initially collected from or in respect of the individual to which such Transferred Information relates and all additional documented purposes where the Disclosing Party has notified the individual of such additional purpose, and where required by Law, obtained the consent of such individual to such use or disclosure.

In addition to its other obligations hereunder, Recipient covenants and agrees to: (i) prior to the completion of the transactions contemplated herein, collect, use and disclose the Transferred Information solely for the purpose of reviewing and completing the transactions contemplated herein, including for the purpose of determining to complete such transactions; (ii) after the completion of the transactions contemplated herein, collect, use and disclose the Transferred Information only for those purposes for which the Transferred Information was initially collected from or in respect of the individual to which such Transferred Information relates or for the completion of the transactions contemplated herein, unless (A) the Disclosing Party or Recipient have first notified such individual of such additional purpose, and where required by Law, obtained the consent of such individual to such additional purpose, or (B) such use or disclosure is permitted or authorized by Law, without notice to, or consent from, such individual; (iii) where required by Law, promptly notify the individuals to whom the Transferred Information relates that the transactions contemplated herein have taken place and that the Transferred Information has been disclosed to Recipient; (iv) return or destroy the Transferred Information, at the option of the Disclosing Party, should the transactions contemplated herein not be completed; and (v) notwithstanding any other provision herein, where the disclosure or transfer of Transferred Information to Recipient requires the consent of, or the provision of notice to, the individual to which such Transferred Information relates, to not require the disclosure or transfer of such Transferred Information until the Disclosing Party has first notified such individual of such disclosure or transfer and the purpose for same, and where required by Law, obtained the individual’s consent to same and to only collect, use and disclose such information to the extent necessary to complete the transactions contemplated herein and as authorized or permitted by Law.

Recipient shall at all times keep strictly confidential all Transferred Information provided to it, and shall instruct those employees or advisors responsible for processing such Transferred Information to protect the confidentiality of such information in a manner consistent with the Recipient’s obligations hereunder and according to Law and agrees to employ appropriate technology and procedures to prevent accidental loss or corruption of such Transferred Information, unauthorized input or access to the Transferred Information, or unauthorized or unlawful collection, storage, disclosure, recording, copying, alteration, removal, deletion, use or other processing of the Transferred Information.

Recipient shall ensure that access to the Transferred Information shall be restricted to those employees or advisors of the respective Recipient who have a bona fide need to access such information in order to complete the transactions contemplated herein.

Each Party shall promptly notify the other Parties of the occurrence, or failure to occur, of any event or state of facts which occurrence or failure would, or would be reasonably likely to:

cause any of the representations or warranties of such Party contained in this Agreement to be untrue or inaccurate in any material respect at any time from the date of this Agreement to the Effective Time if such failure to be true or accurate would cause any condition in Section 6.2(1) [Company Representations and Warranties Condition] or Section 6.3(1) [Purchaser Representations and Warranties Condition], as applicable, to not be satisfied; or

result in the failure to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by such Party under this Agreement if such failure to comply would cause any condition in Section 6.2(2) [Company Covenants Condition] or Section 6.3(2) [Purchaser Covenants Condition], as applicable, to not be satisfied;

Notification provided under this Section 4.9 will not affect the representations, warranties, covenants, agreements or obligations of the Parties (or remedies with respect thereto) or the conditions to the obligations of the Parties under this Agreement. In addition, the failure by any Party to provide a notification pursuant to Section 4.9(1) shall not be considered in determining whether any condition in Section 6.2, Section 6.3(1) or Section 6.3(2) has been satisfied.

The Purchaser may not elect to exercise its right to terminate this Agreement pursuant to Section 7.2(1)(d)(i) [Company Breach of Representations, Warranties or Covenants] and the Company may not elect to exercise its right to terminate this Agreement pursuant to Section 7.2(1)(c)(i) [Purchaser Breach of Representations, Warranties or Covenants], unless the Party seeking to terminate this Agreement (the “Terminating Party”) has delivered a written notice (“Termination Notice”) to the other Party (the “Breaching Party”) specifying in reasonable detail all breaches of covenants, representations and warranties or other matters which the Terminating Party asserts as the basis for termination. After delivering a Termination Notice, provided the Breaching Party is proceeding diligently to cure such matter and such matter is capable of being cured prior to the Outside Date, the Terminating Party may not exercise such termination right until the earlier of (a) the Outside Date, and (b) the date that is 10 Business Days following receipt of such Termination Notice by Breaching Party, if such matter has not been cured by such date. If the Terminating Party delivers a Termination Notice less than 10 Business Days prior to the date of the Company Meeting, unless the Parties agree otherwise, the Company shall postpone or adjourn the Company Meeting to the earlier of (a) five Business Days prior to the Outside Date and (b) the date that is 10 Business Days following receipt of such Termination Notice by the Breaching Party.

Prior to the Effective Date, the Company shall purchase from an insurance carrier with the same or better credit rating as the Company’s current insurance carriers customary “tail” policies of directors’ and officers’ liability insurance providing protection no less favourable in the aggregate than the protection provided by the policies maintained by the Company and the Company Subsidiaries which are in effect immediately prior to the Effective Date and providing protection in respect of claims arising from facts or events which occurred on or prior to the Effective Date and the Purchaser will, or will cause the Company and the Company Subsidiaries to maintain such tail policies in effect without any reduction in scope or coverage for six years from the Effective Date; provided that the Purchaser will not be required to pay any amounts in respect of such coverage prior to the Effective Time and provided further that the cost of such policies shall not exceed 300% of the Company’s and the Company Subsidiaries’ current annual aggregate premium for policies currently maintained by the Company and its Subsidiaries.

The Purchaser shall honour all rights to indemnification or exculpation now existing in favour of present and former employees, officers and directors of the Company and the Company Subsidiaries (each, a “Section 4.10 Indemnified Person”), whether such rights are contractual or are contained in the bylaws of the Company or a Company Subsidiary; and all such rights shall survive the completion of the Plan of Arrangement, shall not be amended or rescinded, and shall continue in full force and effect in accordance with their terms for a period of not less than six years from the Effective Date.

If the Purchaser, the Company or any Company Subsidiaries or any of their respective successors or assigns (i) consolidates with or merges into any other Person and is not a continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties or assets to any Person, the Purchaser shall ensure that any successor or assign (including, as applicable, any acquirer of substantially all of the properties or assets of the Company or Company Subsidiaries) assumes all of the obligations set forth in this Section 4.10.

This Section 4.10 shall survive the consummation of the Arrangement and is intended to be for the benefit of, and shall be enforceable by, each Section 4.10 Indemnified Person and his or her heirs, executors, administrators and personal representatives and shall be binding on the Company and the Purchaser and their respective successors and assigns, and for such purpose, the Company hereby confirms that it is acting as agent and trustee on behalf of the Indemnified Persons; provided, however that no approval of any beneficiary of such trust will be required in connection with any amendment or variation of this Section 4.10 prior to the Effective Time.

The Company agrees that the Company shall, and shall cause each of the Company Subsidiaries to, use commercially reasonable efforts to (i) take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary, proper or advisable under Law to effect such reorganizations of the Company’s or any of the Company Subsidiary’s business, operations and assets as the Purchaser may request, acting reasonably, including if requested by the Purchaser following the Final Order, effect the dissolution or winding up of Merus Pharma Inc. or the amalgamation of Merus Pharma Inc. with the Company (each a “Pre-Acquisition Reorganization”) and (ii) co-operate with the Purchaser and its advisors in order to determine the nature of a Pre-Acquisition Reorganization that might be undertaken and the manner in which they might most effectively be undertaken; provided, however, that: (A) the Pre-Acquisition Reorganization is effected immediately prior to or contemporaneously with the Effective Date and does not require the Company to obtain the approval of the Company Securityholders, (B) the Pre-Acquisition Reorganization does not reduce, or impact the form of, the consideration to be received by the Company Securityholders under the Plan of Arrangement, (C) the Pre-Acquisition Reorganization is not prejudicial to the Company, any Company Subsidiary or the Company Securityholders in any material respect, (D) the Pre-Acquisition Reorganization does not require the Company or any of the Company Subsidiaries to contravene (i) any Laws, or (ii) its or their respective organizational documents, (E) the Pre-Acquisition Reorganization does not impair, prevent or delay the consummation of the Arrangement or the ability of the Purchaser to obtain any financing required by it in connection with the transactions contemplated by this Agreement, (F) the Pre-Acquisition Reorganization does not impede, delay or prevent the receipt of any governmental or third party approval or consent or the satisfaction of any other conditions set forth in Article 6, (G) the Pre-Acquisition Reorganization does not result in Taxes being imposed on, or other adverse Tax consequences to, any Company Securityholder or the Company Securityholders generally that are materially greater than the Taxes imposed on or other consequences to the Company Securityholders in connection with the completion of the Arrangement in the absence of such Pre-Acquisition Reorganization, (H) the Pre-Acquisition Reorganization shall not become effective unless the Purchaser has waived or confirmed in writing the satisfaction of all conditions in its favour under Section 6.1 and Section 6.2 and have confirmed in writing that each of them is prepared, and able to promptly and without condition (other than compliance with this Section 4.11) proceed to effect the Arrangement, (I) any such requested cooperation does not require the directors, officers, employees or agents of the Company or the Company Subsidiaries to take any action in any capacity other than as a director, officer or employee of the applicable entity, and (J) the Pre-Acquisition Reorganization does not unreasonably or materially interfere with the operations of the Company or any of the Company Subsidiaries prior to or as at the Effective Time. The Purchaser acknowledges and agrees that any Pre-Acquisition Reorganization shall not be considered in determining whether a representation, warranty or covenant of the Company hereunder has been breached.

The Purchaser shall provide written notice to the Company of any Pre-Acquisition Reorganization at least 15 Business Days prior to the Effective Date. The Purchaser shall (A) forthwith pay (or if paid by Company, forthwith reimburse the Company for) all reasonable fees, direct or indirect costs, liabilities, fees, damages, penalties, Taxes and expenses, including legal fees and disbursements, incurred by the Company and the Company Subsidiaries in considering, effecting, cooperating, implementing, modifying, termination or otherwise in connection with any Pre-Acquisition Reorganizations (whether proposed or completed), and (B) if the Arrangement is not completed as contemplated herein, indemnify and save harmless the Company, the Company Subsidiaries and their respective Representatives from and against any and all liabilities, losses, damages, claims, costs, expenses, interest, awards, judgements, penalties and Taxes suffered or incurred by any of them in connection with or as a result of any Pre-Acquisition Reorganization (including in connection with considering, effecting, cooperating, implementing, modifying or terminating any such reorganization) or to reverse or unwind any Pre-Acquisition Reorganization. The obligations of the Purchaser hereunder shall survive termination of this Agreement. The obligation of the Purchaser to make the payments, reimbursements and indemnities set out in this Section 4.11 will be in addition to any other payment the Purchaser may be obligated to make hereunder and will survive termination of this Agreement. The completion of a Pre-Acquisition Reorganization shall not be a condition to the consummation of the Arrangement.

Except as expressly provided in this Article 5 from the date of this Agreement until the Effective Time or, if earlier, the termination of this Agreement in accordance with Article 7, the Company shall not, directly or indirectly, through any officer, director, employee, shareholder, representative (including any financial or other adviser) or agent of the Company or of any Company Subsidiary (collectively, “Representatives”), or otherwise, and shall not permit any such Representative to:

solicit, assist, initiate or knowingly take any action with the intent of encouraging or facilitating (including by way of furnishing or providing copies of, access to, or disclosure of, any confidential information, properties, facilities, books or records of the Company or any Company Subsidiary or entering into any form of agreement, arrangement or understanding) any inquiry, proposal or offer that constitutes, or may reasonably be expected to constitute or lead to, an Acquisition Proposal;

enter into or otherwise engage or participate in any discussions or negotiations with any Person (other than the Purchaser or any Person acting jointly or in concert with the Purchaser) regarding any inquiry, proposal or offer that constitutes, or may reasonably be expected to constitute or lead to, an Acquisition Proposal; provided that, for greater certainty, the Company shall be permitted to: (i) communicate with any Person for the purposes of clarifying the terms of any inquiry, proposal or offer made by such Person; (ii) advise any Person of the restrictions of this Agreement; and (iii) advise any Person making an Acquisition Proposal that the Board has determined that such Acquisition Proposal does not constitute or is not reasonably expected to constitute or lead to a Superior Proposal;

make a Change in Recommendation;

accept, approve, endorse or recommend, or publicly propose to or state an intention to accept, approve, endorse or recommend, or take no position or remain neutral with respect to, any Acquisition Proposal (it being understood that publicly taking no position or a neutral position with respect to a publicly announced, or otherwise publicly disclosed, Acquisition Proposal for a period of no more than five (5) Business Days following such disclosure will not be considered to be in violation of this Section 5.1 provided that the Board has rejected such Acquisition Proposal and affirmed the Board Recommendation before the end of such five (5) Business Day period); or

accept or enter into (other than a confidentiality agreement permitted by and in accordance with Section 5.3) or publicly propose to or state an intention to accept or enter into any agreement, understanding or arrangement in respect of an Acquisition Proposal.

The Company shall, and shall cause the Company Subsidiaries and their respective Representatives to, immediately cease and terminate, and cause to be terminated, any solicitation, encouragement, discussion, negotiation, or other activities commenced prior to the date of this Agreement with any Person (other than the Purchaser) with respect to any inquiry, proposal or offer with respect to any inquiry, proposal or offer that constitutes, or may reasonably be expected to constitute or lead to, an Acquisition Proposal, and in connection therewith: (a) the Company will immediately discontinue access to and disclosure of all information, including any data room and any confidential information, properties, facilities, books and records of the Company or of any Company Subsidiary; and (b) within two (2) Business Days of the date of this Agreement, request (i) the return or destruction of all copies of any confidential information regarding the Company or any Company Subsidiary provided to any Person other than the Purchaser, and (ii) the destruction of all material including or incorporating or otherwise reflecting such confidential information regarding the Company or any Company Subsidiary, to the extent that such information has not previously been returned or destroyed, using its commercially reasonable efforts to ensure that such requests are complied with in accordance with the terms of such rights.

The Company shall use commercially reasonable efforts to (a) enforce any confidentiality, standstill or similar agreement or covenant to which the Company or any Company Subsidiary is a party or in favour of the Company or any Company Subsidiary, and (b) other than to permit a Person to make a confidential Acquisition Proposal to the Company and/or the Board and/or the Special Committee, not to release, and to cause its Subsidiaries not to release, any Person from, or waive, amend, suspend or otherwise modify such Person’s obligations respecting the Company, or any of the Company Subsidiaries, under any confidentiality, standstill or similar agreement or covenant to which the Company or any Company Subsidiary is a party or in favour of the Company or any Company Subsidiary, without the prior written consent of the Purchaser (which may be withheld or delayed in the Purchaser’s sole and absolute discretion), it being acknowledged by the Purchaser that the automatic termination or release of any standstill or similar restrictions of any such agreements as a result of entering into and announcing this Agreement shall not be a violation of this Section 5.1(3); provided, however that nothing in this Agreement shall prevent the Company and/or the Board and/or the Special Committee from considering a confidential Acquisition Proposal that is made to the Company and/or the Board and/or the Special Committee from a Person that is restricted from making an Acquisition Proposal and accepting a Superior Proposal that might be made by any such Person.

Notwithstanding Section 5.1 or any other agreement between the Parties or between the Company and any other Person, if at any time prior to approval of the Arrangement Resolution in accordance with the Interim Order the Company receives a bona fide written Acquisition Proposal, the Company and its Representatives may engage in or participate in discussions or negotiations with such Person regarding such Acquisition Proposal, and may provide copies of, access to or disclosure of information, properties, facilities, books or records of the Company and the Company Subsidiaries, if and only if:

the Board first determines in good faith, after consultation with its financial advisors and its outside legal counsel, that such Acquisition Proposal constitutes or could reasonably be expected to constitute or lead to a Superior Proposal;

the Acquisition Proposal did not result from the breach of the Company’s obligations under this Article 5; and

prior to providing any such copies, access, or disclosure, (i) the Company shall have entered into a confidentiality agreement with such Person containing provisions that are not materially less favourable to the Company than those found in the Confidentiality Agreement in any material respect (for the avoidance of doubt, it being understood and agreed that such confidentiality agreement need not restrict the making of a confidential Acquisition Proposal or consummating a Superior Proposal), and (ii) any such copies, access or disclosure provided to such Person shall have already been (or simultaneously be) provided to the Purchaser (by posting such information to the Data Room or otherwise).

If the Company receives an Acquisition Proposal that constitutes a Superior Proposal prior to the approval of the Arrangement Resolution in accordance with the Interim Order, the Board may make a Change in Recommendation and/or, subject to compliance with Section 8.2(3), enter into a definitive agreement with respect to such Superior Proposal, if and only if:

the Superior Proposal did not result from the breach of the Company’s obligations under this Article 5 and the Company continues to be in compliance with its obligations under this Article 5;

the Company has delivered to the Purchaser a copy of any proposed agreement in respect of the Superior Proposal;

the Company has delivered to the Purchaser written notice of the determination of the Board that the relevant Acquisition Proposal constitutes a Superior Proposal, and of the intention of the Board to make a Change in Recommendation and/or enter into such definitive agreement with respect to such Superior Proposal (the “Superior Proposal Notice”);

at least five (5) Business Days have elapsed from the date that is the later of the date on which the Purchaser received the Superior Proposal Notice and the date on which the Purchaser received a copy of the proposed definitive agreement for the Superior Proposal from the Company (the “Matching Period”);

during any Matching Period, the Purchaser has had the opportunity (but not the obligation), in accordance with Section 5.4(2), to offer to amend this Agreement and the Arrangement in order for such Acquisition Proposal to cease to be a Superior Proposal;

after the Matching Period, the Board (i) has determined in good faith, after consultation with its outside legal counsel and financial advisors, that such Acquisition Proposal continues to constitute a Superior Proposal (if applicable, compared to the terms of the Arrangement as proposed to be amended by the Purchaser under Section 5.4(2)) and (ii) has determined in good faith, after consultation with its outside legal counsel and financial advisors, that the failure by the Board to make a Change in Recommendation and/or authorize the Company to enter into a definitive agreement with respect to such Superior Proposal would be inconsistent with its fiduciary duties; and

prior to or concurrently with entering into such definitive agreement the Company terminates this Agreement pursuant to Section 7.2(1)(c)(ii) and pays the Termination Fee pursuant to Section 8.2(3).

During the Matching Period, or such longer period as the Company may, in its sole discretion, approve in writing for such purpose: (a) the Board shall review any offer made by the Purchaser under Section 5.4(1)(d) to amend the terms of this Agreement and the Arrangement in good faith in order to determine whether such offer would, upon acceptance, result in the Acquisition Proposal previously constituting a Superior Proposal ceasing to be a Superior Proposal; and (b) the Company shall negotiate in good faith with the Purchaser to make such amendments to the terms of this Agreement and the Arrangement as would enable the Purchaser to proceed with the transactions contemplated by this Agreement on such amended terms. If the Board determines that such Acquisition Proposal would cease to be a Superior Proposal, the Company shall promptly so advise the Purchaser and the Company and the Purchaser shall amend this Agreement to reflect such offer made by the Purchaser, and shall take and cause to be taken all such actions as are necessary to give effect to the foregoing.

Each successive amendment or modification to any Acquisition Proposal that results in an increase in, or modification of, the consideration (or value of such consideration) to be received by the holders of Common Shares or other material terms or conditions thereof shall constitute a new Acquisition Proposal for the purposes of this Section 5.4, and the Purchaser shall be afforded a five day Matching Period from the date on which the Purchaser received the Superior Proposal Notice with respect to the new Superior Proposal from the Company.

At the written request of the Purchaser, the Board shall reaffirm the Board Recommendation by press release if the Board determines that a proposed amendment to the terms of this Agreement as contemplated under Section 5.4(2) would result in an Acquisition Proposal no longer being a Superior Proposal. The Company shall provide the Purchaser and its outside legal counsel with a reasonable opportunity to review the form and content of any such press release and shall make all reasonable amendments to such press release as requested by the Purchaser.

If the Company provides a Superior Proposal Notice to the Purchaser on a date that is less than 3 Business Days before the Company Meeting, the Company shall either proceed with or shall postpone the Company Meeting to a date that is not more than 3 Business Days after the scheduled date of the Company Meeting, as directed by the Purchaser, acting reasonably, but in any event the Company Meeting shall not be postponed to a date which would prevent the Effective Date from occurring on or prior to the Outside Date.

The Company shall advise the Company Subsidiaries and their respective Representatives of the prohibitions set out in this Article 5 and any violation of the restrictions set forth in this Article 5 by the Company, the Company Subsidiaries or their respective Representatives is deemed to be a breach of this Article 5 by the Company.

Nothing contained in this Article 5 shall prohibit the Board from:

responding through a directors’ circular or otherwise as required by Law to an Acquisition Proposal, provided that the Company shall provide the Purchaser and its outside legal counsel with a reasonable opportunity to review the form and content of such circular or other disclosure and shall make all reasonable amendments as requested by the Purchaser and its counsel; or

calling and/or holding a meeting of Common Shareholders requisitioned by Common Shareholders in accordance with the BCBCA or taking any other action with respect to an Acquisition Proposal to the extent ordered or otherwise mandated by a court of competent jurisdiction in accordance with Law.

Arrangement Resolution. The Arrangement Resolution has been approved and adopted at the Company Meeting in accordance with the Interim Order.

Interim Order and Final Order. The Interim Order and the Final Order have each been obtained on terms consistent with this Agreement, and have not been set aside or modified in a manner unacceptable to either the Company or the Purchaser, each acting reasonably, on appeal or otherwise.

Regulatory Approvals. The Required Regulatory Approval has been obtained.

Illegality. No Law is in effect that makes the consummation of the Arrangement illegal or otherwise prohibits or enjoins the Company or the Purchaser from consummating the Arrangement.

Representations and Warranties. The representations and warranties of the Company set forth in this Agreement which are qualified by references to materiality or by the expression “Material Adverse Effect” and the representations and warranties of the Company set forth in Sections (2), (3), (6) and the first sentence of Section 1 of Schedule C were true and correct as of the date of this Agreement and are true and correct as of the Effective Time in all respects (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date and except for de minimis inaccuracies, changes reflecting the exercise, conversion, termination or expiry of any Company Options, Company PSUs, or Company Preferred Shares or reflecting the grant of Company Options or Company PSUs), and all other representations of the Company set forth in this Agreement were true and correct as of the date of this Agreement and are true and correct as of the Effective Time in all material respects (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date); except, in each case, to the extent that the failure or failures of such representations and warranties to be so true and correct, individually or in the aggregate, would not have a Material Adverse Effect (and, for this purpose, any reference to “material”, “Material Adverse Effect”, or other concepts of materiality in such representations and warranties shall be ignored), and the Company has delivered a certificate confirming the same to the Purchaser, executed by two senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.

Performance of Covenants. The Company has fulfilled or complied in all material respects with each of the covenants of the Company contained in this Agreement to be fulfilled or complied with by it on or prior to the Effective Time, and the Company has delivered a certificate confirming the same to the Purchaser, executed by two senior officers of the Company (in each case without personal liability) addressed to the Purchaser and dated the Effective Date.

Material Adverse Effect. There shall not have occurred a Material Adverse Effect since the date of this Agreement and prior to the Effective Date.

Dissent Rights. Dissent Rights have not been exercised with respect to more than 15% of the issued and outstanding Common Shares.

Representations and Warranties. The representations and warranties of the Purchaser set forth in this Agreement which are qualified by references to materiality were true and correct as of the date of this Agreement and are true and correct as of the Effective Time in all respects (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date) and all other representations and warranties of the Purchaser set forth in this Agreement were true and correct as of the date of this Agreement and are true and correct as of the Effective Time in all material respects (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of such specified date), and the Purchaser has delivered a certificate confirming same to the Company, executed by two senior officers of the Purchaser (in each case without personal liability) addressed to the Company and dated the Effective Date.

Performance of Covenants. The Purchaser has fulfilled or complied in all material respects with each of the covenants of the Purchaser contained in this Agreement to be fulfilled or complied with by them on or prior to the Effective Time, and the Purchaser has delivered a certificate confirming same to the Company, executed by two senior officers of the Purchaser (in each case without personal liability) addressed to the Company and dated the Effective Date.

Payment. The Purchaser shall have deposited or caused to be deposited with the Depositary in escrow the amounts contemplated by Section 2.9 and the Depositary shall have confirmed to the Company receipt of these funds.

This Agreement may be terminated prior to the Effective Time by:

the mutual written agreement of the Parties; or

any of the Company or the Purchaser if:

the Company Meeting is duly convened and held and the Arrangement Resolution is voted on by Common Shareholders and is not approved by the Common Shareholders at the Company Meeting in accordance with the Interim Order;

after the date of this Agreement, any Law is enacted, made, enforced or amended, as applicable, that makes the consummation of the Arrangement illegal or otherwise prohibits or enjoins the Company or the Purchaser from consummating the Arrangement, and such Law has, if applicable, become final and non-appealable, provided the Party seeking to terminate has complied with its obligations under Section 4.2(1)(d) or Section 4.3(1)(d), as applicable, and provided further that the enactment, making, enforcement or amendment of such Law was not primarily due to the failure of such Party to perform any of its covenants or agreements under this Agreement; or

the Effective Time does not occur on or prior to the Outside Date, provided that a Party may not terminate this Agreement pursuant to this Section 7.2(1)(b)(iii) if the failure of the Effective Time to so occur has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under this Agreement; or

the Company if:

(i)

a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Purchaser under this Agreement occurs that would cause any condition in Section 6.3(1) [Purchaser Representations and Warranties] or Section 6.3(2) [Purchaser Performance of Covenants] not to be satisfied, and such breach or failure is incapable of being cured or is not cured in accordance with the terms of Section 4.9(3) (provided that any Wilful Breach shall be deemed to be incapable of being cured) and the Company is not then in breach of this Agreement so as to cause any condition in Section 6.2(1) [Company Representations and Warranties] or Section 6.2(2) [Company Performance of Covenants] not to be satisfied; or

prior to approval of the Arrangement Resolution in accordance with the Interim Order, the Board authorizes the Company to enter into a written agreement (other than a confidentiality agreement permitted and in accordance with Section 5.3) with respect to a Superior Proposal in accordance with Section 5.4, provided that the Company is then in compliance with Article 5 and that prior to or concurrent with such termination the Company pays the Termination Fee; or

the Purchaser if:

a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the Company under this Agreement occurs that would cause any condition in Section 6.2(1) [Company Representations and Warranties] or Section 6.2(2) [Company Performance of Covenants] not to be satisfied, and such breach or failure is incapable of being cured or is not cured in accordance with the terms of Section 4.9(3) (provided that any Wilful Breach shall be deemed to be incapable of being cured) and the Purchaser is not then in breach of this Agreement so as to cause any condition in Section 6.3(1) [Purchaser Representations and Warranties] or Section 6.3(2) [Purchaser Performance of Covenants] not to be satisfied;

prior to approval of the Arrangement Resolution in accordance with the Interim Order (A) the Board or any committee of the Board fails to unanimously recommend or withdraws, amends, modifies or adversely qualifies, or publicly proposes or states an intention to withdraw, amend, modify or adversely qualify, or fails to publicly reaffirm (without qualification) within two (2) Business Days after the written request by Purchaser, the Board Recommendation (it being understood that the Board will have no obligation to make such reaffirmation on more than two (2) separate occasions), (B) the Board or any committee of the Board accepts, approves, endorses or recommends, or publicly proposes to accept, approve, endorse or recommend an Acquisition Proposal or takes no position or remains neutral with respect to a publicly announced, or otherwise publicly disclosed, Acquisition Proposal for more than five (5) Business Days, (together with any of the matters set forth in (A), a “Change in Recommendation”), or (C) or the Company Wilfully Breaches Section 5.1(1); or

an event has occurred as a result of which the condition set forth in [Material Adverse Effect] is not capable of being satisfied by the Outside Date.

Subject to Section 4.9(3), if applicable, the Party desiring to terminate this Agreement pursuant to this Section 7.2 (other than pursuant to Section 7.2(1)(a)) shall give notice of such termination to the other Parties, specifying in reasonable detail the basis for such Party’s exercise of its termination right.

change the time for performance of any of the obligations or acts of the Parties;

modify any representation or warranty contained in this Agreement or in any document delivered pursuant to this Agreement;

modify any of the covenants contained in this Agreement and waive or modify performance of any of the obligations of the Parties; and/or

modify any mutual conditions contained in this Agreement.

Despite any other provision in this Agreement relating to the payment of fees and expenses, including the payment of brokerage fees, if a Termination Fee Event occurs, the Company shall pay to the Purchaser or as it directs the Termination Fee in accordance with Section 8.2(3).

For the purposes of this Agreement, “Termination Fee Event” means the termination of this Agreement:

by the Purchaser, pursuant to Section 7.2(1)(d)(ii) [Change of Recommendation or Wilful Breach of Section 5.1(1)];

by the Company, pursuant to Section 7.2(1)(c)(ii) [Superior Proposal]; or

by the Company or the Purchaser pursuant to Section 7.2(1)(b)(i) [Arrangement Resolution Not Approved], or by the Purchaser pursuant to Section 7.2(1)(d)(i) [Breach of Representations and Warranties or Covenants by Company] as a result of a Wilful Breach, if:

following the date hereof and prior to the Company Meeting a bona fide Acquisition Proposal involving the Company is publicly announced or otherwise publicly disclosed by any Person (other than the Purchaser or any of its affiliates or any Person acting jointly or in concert with any of the foregoing); and

within 12 months following the date of such termination, (A) a definitive agreement is entered into by the Company with respect to any Acquisition Proposal (whether or not the Acquisition Proposal referred to in (i)) and such Acquisition Proposal (whether or not amended) is consummated at any time thereafter or (B) any Acquisition Proposal (whether or not the Acquisition Proposal referred to in (i)) is consummated.

If a Termination Fee Event occurs, the Company shall pay the Termination Fee as follows:

if the Termination Fee is payable pursuant to Section 8.2(2)(a), the Termination Fee shall be paid within five Business Days following such Termination Fee Event;

if the Termination Fee is payable pursuant to Section 8.2(2)(b), the Termination Fee shall be paid prior to or concurrently with the occurrence of such Termination Fee Event; or

if the Termination Fee is payable pursuant to Section 8.2(2)(c), the Termination Fee shall be paid concurrently with the consummation of the Acquisition Proposal referred to therein.

Except as set forth in Section 2.3(b) [Proxy Solicitation Expenses], Section 2.4(4) [Purchaser Information Indemnity], Section 4.4(7) [Regulatory Fees], Section 4.5(6) [Financing Indemnity/Expenses], and Section 4.11(2) [Pre-Acquisition Reorganization Indemnity/Expenses], all out-of-pocket third party transaction expenses incurred in connection with this Agreement and the Plan of Arrangement, including all costs, expenses and fees of the Company incurred prior to or after the Effective Time in connection with, or incidental to, the Plan of Arrangement, shall be paid by the Party incurring such expenses, whether or not the Arrangement is consummated.

In addition to the rights of the Purchaser under Section 8.2(1), if this Agreement is terminated by the Purchaser pursuant to Section 7.2(1)(b)(i) [Arrangement Resolution Not Approved] or pursuant to Section 7.2(1)(d)(i) [Breach of Representations and Warranties or Covenants by Company] as a result of a Wilful Breach, then the Company shall, within five (5) Business Days of such termination, pay or cause to be paid to the Purchaser (or as the Purchaser may direct by notice in writing) by wire transfer of immediately available funds an expense reimbursement fee for reasonable, documented out-of-pocket third party transaction expenses incurred by the Purchaser in connection with this Agreement, an amount not to exceed $2.5 million, provided that in no event shall the Company be required to pay under Section 8.2(1) and this Section 8.3(2), in the aggregate, an amount in excess of the Termination Fee. For greater certainty, any payment by the Company under this Section 8.3(2) will be credited against a payment under Section 8.2(1).

to the Purchaser at:

Norgine BV
▇▇▇▇▇▇▇▇▇▇ ▇

▇▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇

▇▇▇▇▇▇▇▇▇:        ▇▇▇▇▇ ▇▇▇▇▇
Telephone:      ▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇
E-mail:               ▇▇▇▇▇▇@▇▇▇▇▇▇▇.▇▇▇

Stikeman Elliott LLP

Attention:        ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Telephone:       (▇▇▇) ▇▇▇-▇▇▇▇
E-mail:               ▇▇▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇.▇▇▇

to the Company at:

▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇. ▇▇▇▇
▇▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇

Attention:        ▇▇▇▇▇ ▇▇▇▇▇▇▇
Telephone:       (▇▇▇) ▇▇▇-▇▇▇▇

E-mail:               ▇▇▇▇▇▇▇▇@▇▇▇▇▇▇▇▇▇.▇▇▇

Except as otherwise provided in this Agreement, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy expressly conferred hereby, and the exercise by a Party of any one such remedy will not preclude the exercise of any other such remedy (it being understood that in no event shall the Company be required to pay the Termination Fee on more than one occasion.

The Parties agree that irreparable harm would occur for which money damages would not be an adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that, unless this Agreement has been terminated in accordance with its terms, the Parties shall be entitled to injunctive and other equitable relief to prevent or restrain breaches or threatened breaches of this Agreement and to specifically enforce the performance of, or compliance with, the terms of this Agreement without any requirement for the securing or posting of any bond in connection with the obtaining of any such injunctive or other equitable relief. Subject to the foregoing, each Party hereby agrees not to raise any objections to the availability of the equitable remedies provided for herein and, except as provided in Section 8.6(4), the Parties further agree that (X) by seeking the remedies provided for in this Section 8.6(2), a Party shall not in any respect waive its right to seek any other form of relief that may be available to a Party under this Agreement (including monetary damages), and (Y) nothing set forth in this Section 8.6(2) shall require any Party hereto to institute any Proceeding for (or limit any Party’s right to institute any Proceeding for) specific performance under this Section 8.6(2) prior or as a condition to exercising any termination right under this Agreement (and/or receipt of any amounts due in connection with such termination), nor shall the commencement of any legal action or legal proceeding pursuant to this Section 8.6(2) or anything set forth in this Section 8.6(2) restrict or limit any Party’s right to terminate this Agreement in accordance with the terms hereof, or pursue any other remedies under this Agreement that may be available then or thereafter.

Each of the Parties acknowledges that the agreements contained in Section 8.2 are an integral part of the transactions contemplated by this Agreement, and that without these agreements the Parties would not enter into this Agreement, and that the Termination Fee set out in Section 8.2 represent liquidated damages which are a genuine pre-estimate of the damages, including opportunity costs, which the Purchaser will suffer or incur as a result of the event giving rise to such damages and resultant termination of this Agreement, and are not penalties. The Company irrevocably waives any right it may have to raise as a defence that any such liquidated damages are excessive or punitive. Notwithstanding anything to the contrary in this Agreement, in the event of the termination of this Agreement in accordance with its terms in circumstances that constitute a Termination Fee Event, the payment of the Termination Fee pursuant to Section 8.2(3) shall be the sole and exclusive remedy of the Purchaser and its affiliates (including damages, specific performance and injunctive relief) against the Company, the Company Subsidiaries and any of their respective former, current or future direct or indirect directors, officers, employees, shareholders, affiliates, agents, members, managers, general or limited partners, or any former, current or future direct or indirect directors, officers, employees, shareholders, affiliates, agents, members, managers, general or limited partners or assignees of any of the foregoing (collectively, the “Company Related Parties”) for any loss suffered relating to or arising out of this Agreement or any agreement executed in connection herewith or the transactions contemplated hereby or thereby, including any breach of this Agreement, the termination of this Agreement or the failure of the transactions contemplated by this Agreement to be consummated, and upon payment in full of the Termination Fee pursuant to Section 8.2(3), none of the Company, the Company Subsidiaries or any of their respective Company Related Parties shall have any further liability or obligation relating to or arising out of this Agreement or any agreement executed in connection therein or the transactions contemplated hereby or thereby or any claims or actions under applicable Law arising out of any such breach, termination or failure; provided, however, that the foregoing shall not limit the right of the Purchaser to seek specific performance of this Agreement pursuant to Section 8.6(2) prior to the termination of this Agreement.

Notwithstanding anything to the contrary in this Agreement, in no event shall the Purchaser be entitled to seek or obtain any recovery or judgment including damages of any kind against the Company, the Company Subsidiaries or any of their respective Company Related Parties, or any of their respective assets that in aggregate exceed the Termination Fee and provided, further, however, this Section 8.6(4) shall not limit the right of any Party hereto to seek specific performance of this Agreement pursuant to, and subject to the limitations in, Section 8.6(2) prior to the termination of this Agreement; and provided, further, that in no event will the Purchaser be entitled to both (x) the payment of the Termination Fee, as applicable, and (y) the grant of specific performance of this Agreement resulting in the consummation of the Closing as contemplated by this Agreement.

(1)

Except (i) as provided in Section 2.4(4) [Purchaser Information Indemnity], Section 4.5(6) [Financing Indemnity/Expenses], Section 4.10, Section 4.11(2) [Pre-Acquisition Reorganization Indemnity/Expenses], this Section 8.7 and Section 8.14 which, without limiting their terms, are intended as stipulations for the benefit of the third Persons mentioned in such provisions (such third Persons referred to in this Section 8.7 as the “Indemnified Persons”), (ii) the rights of the Company to pursue claims for damages and other relief on behalf of holders of Common Shares, Company Options and Company PSUs for the Purchaser’s breach of the terms of this Agreement and (iii) after the Effective Date, the rights of Common Shareholders to receive the Consideration and the rights of the holders of Company Options and Company PSUs to receive the payments provided for under the Arrangement, the Company and the Purchaser intend that this Agreement will not benefit or create any right or cause of action in favour of any Person, other than the Parties and that no Person, other than the Parties, shall be entitled to rely on the provisions of this Agreement in any action, suit, proceeding, hearing or other forum; provided however that the rights granted pursuant to clause (ii) of this paragraph shall be enforceable on behalf of the holders of Common Shares, Company Options and Company PSUs only by the Company in its sole and absolute discretion, it being understood and agreed that any all interest in such claims shall attach to the Common Shares, Company Options and Company PSUs and subsequently trade and transfer therewith and, consequently, damages recovered or received by the Company with respect to such claims (net of expenses incurred by the Company in connection therewith) may, in the Company’s sole and absolute discretion, be (A) distributed, in whole or in part, by the Company to the holders of Common Shares, Company Options and Company PSUs as of any record date determined by the Company, which determination may be made by the Company as of any date or (B) retained by the Company for use and benefit of the Company on behalf of its shareholders in any manner the Company deems fit. To the extent necessary to give effect to clauses (ii) and (iii), the Purchaser agrees that all of its covenants, representations and warranties are in favour of the Company in its own right and as agent and trustee for the holders of Common Shares, Company Options and Company PSUs, but without any fiduciary obligations on the Company in relation thereto.

Despite the foregoing, the Parties acknowledge to each of the Indemnified Persons their direct rights against the applicable Party under the provisions described in clause (i) of paragraph (1) above, which are intended for the benefit of, and shall be enforceable by, each Indemnified Person, his or her heirs, executors, administrators, successors, assigns and his or her legal representatives, and for such purpose, the Company or the Purchaser, as applicable, confirms that it is acting as trustee on their behalf, and agrees to enforce such provisions on their behalf, provided, however, that no approval of any beneficiary of such trust will be required in connection any amendment or variation of the provisions described in clause (i) of paragraph (1) above prior to the Effective Date.

This Agreement will be binding upon and enure to the benefit of the Company and the Purchaser and their respective successors and permitted assigns.

Neither this Agreement nor any of the rights or obligations under this Agreement are assignable or transferable by any Party without the prior written consent of the other Party; provided that the Purchaser may assign all or any part of its rights under this Agreement to, and its obligations under this Agreement may be assumed by, a Subsidiary of the Purchaser, provided that if such assignment and/or assumption takes place, the Purchaser shall continue to be liable jointly and severally with such Subsidiary for all of its obligations hereunder.

This Agreement will be governed by and interpreted and enforced in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.

Each Party irrevocably attorns and submits to the exclusive jurisdiction of the Ontario courts situated in the City of Toronto and waives objection to the venue of any proceeding in such court or that such court provides an inconvenient forum.

The Purchaser hereby irrevocably designates Stikeman Elliott LLP (in such capacity, the “Process Agent”), ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇, ▇▇▇ ▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇, as its designee, appointee and agent to receive, for and on its behalf, service of process in such jurisdiction in any Proceedings with respect to this Agreement or the transactions contemplated hereby, and such service shall be deemed complete upon delivery thereof to the Process Agent; provided that in the case of any such service upon the Process Agent, the Party effecting such service shall also deliver a copy thereof to the Purchaser in the manner provided in Section 8.4. The Purchaser shall take all such action as may be necessary to continue said appointment in full force and effect or to appoint another agent so that the Purchaser shall at all times have an agent for service of process for the above purposes in the Province of Ontario. In the event of the transfer of all or substantially all of the assets and business of the Process Agent to any other entity by consolidation, merger, sale of assets or otherwise, such other entity shall be substituted hereunder for the Process Agent with the same effect as if named herein in place of Stikeman Elliott LLP. Nothing herein shall affect the right of any Party to serve process in any manner permitted by Law. The Purchaser expressly acknowledges that the waiver as provided in this Section 8.12(3) is intended to be irrevocable under all Laws.

in respect of a Company Option, the amount by which the Consideration multiplied by the number of Common Shares subject to the Company Option exceeds the exercise price payable under such Company Option by the holder thereof; and

in respect of a Company PSU, an amount equal to the number of Common Shares subject to the Company PSU immediately prior to the Effective Time, multiplied by the Consideration;

notwithstanding any vesting or exercise provisions to which a Company Option or Company PSU might otherwise be subject (whether by contract, the conditions of a grant, applicable Law or the terms of the Stock Option Plan or PSU Plan) each Company Option and Company PSU issued and outstanding at the Effective Time will, without any further action by or on behalf of any holder of such Company Option or Company PSU, be deemed to be fully vested and all of the outstanding Company Option or Company PSU, without any further action on behalf of the holder thereof and without any payment except as provided in this Plan of Arrangement and notwithstanding the terms of the Stock Option Plan or PSU Plan, as the case may be, shall be disposed of and surrendered by the holders thereof to the Company without any act or formality on its or their part in exchange for the Cash-Out Consideration (other than Company Options where the Cash- Out Consideration is nil, such Company Options to be disposed of and surrendered by the holders thereof to the Company without any act or formality on its or their part in exchange for no consideration), and the holder of such Company Option or Company PSU will cease to be the holder of such Company Option or Company PSU, will cease to have any rights as a holder in respect of such Company Option or Company PSU under the Stock Option Plan or PSU Plan, such holder’s name will be removed from the Company’s register of Company Options or Company PSUs, and all agreements, grants and similar instruments relating thereto will be cancelled;

each Dissent Share held by a Dissenting Shareholder entitled to be paid fair value for its Dissent Shares will be deemed to be transferred by the holder thereof, without any further act or formality on its part, free and clear of all liens, charges, encumbrances and any other rights of others, to the Purchaser in consideration for a debt claim against the Purchaser in an amount determined in accordance with Article 4 and thereupon each Dissenting Shareholder will have only the rights set out in Article 4 and each Dissenting Shareholder will cease to be the holder of such Common Shares;

each outstanding Common Share (other than those Common Shares acquired by the Purchaser from Dissenting Shareholders under Section 3.1(b)), will be transferred to, and acquired by the Purchaser, free and clear of all liens, charges, encumbrances and any other rights of others, in exchange for a cash payment equal to the Consideration and, in respect of each Common Share:

each former holder of Common Shares will cease to be the holder of such Common Shares so exchanged concurrently with the exchanges referred to in this Section 3.1(c) and such holder’s name will be removed from the register of holders of Common Shares at such time; and

the Purchaser will be deemed to be the holder of such Common Shares (free and clear of all liens, charges, encumbrances and any other rights of others) on the Effective Date and will be entered in the Company’s register of holders of Common Shares as the holder thereof;

the PSU Plan and the Stock Option Plan shall be terminated (and all rights issued thereunder shall expire) and shall be of no further force or effect; and

the Company issues to the Purchaser Common Shares of the Company in consideration for the cash consideration deposited by the Purchaser with the Depositary, on behalf and at the direction of the Company, pursuant to Section 5.1(b).

Adjustments to Consideration

If, on or after the date hereof but prior to the Effective Time, the Company sets a record date for any dividend or other distribution on the Common Shares that is prior to the Effective Time or the Company pays any dividend or other distribution on the Common Shares prior to the Effective Time: (i) to the extent that the amount of such dividends or distributions per Common Share, as applicable, does not exceed the Consideration, the Consideration shall be reduced by the amount of such dividends or distributions; and (ii) to the extent that the amount of such dividends or distributions per Common Share exceeds the Consideration, such excess amount shall be placed in escrow for the account of Purchaser or another Person designated by Purchaser.

Delivery of Consideration

At or prior to the Effective Date, the Purchaser will deposit with the Depositary in accordance with the Arrangement Agreement, cash in an amount sufficient to pay the aggregate Consideration to which the Common Shareholders are entitled to receive in accordance with Article 3 hereof.

At or prior to the Effective Date, in consideration for the Company agreeing to issue to the Purchaser on the Effective Date at the time and in accordance with Section 3.1(e), Common Shares in the capital of the Company, the Purchaser, on behalf and at the direction of the Company, will deposit with the Depositary cash in an amount sufficient to pay the aggregate cash consideration to which the holders of Company Options or Company PSUs are entitled to receive in accordance with Article 3 hereof.

Following the deposit with the Depositary of the amounts specified in Sections 5.1(a) and 5.1(b), the Purchaser will be fully and completely discharged from its obligation to pay the Consideration to the former Common Shareholders and the Company shall be fully and completely discharged from its payment obligations to former holders of Company Options and Company PSUs, respectively, and the rights of such holders will be limited to receiving, from the Depositary, the Consideration or the Cash-Out Consideration to which they are entitled in accordance with this plan of arrangement.

As soon as practicable after the Effective Time, the Depositary shall deliver on behalf of the Company to each holder of Company Options and Company PSUs immediately prior to the Effective Time, as reflected on the books and records of the Company, a cheque (or other form of payment of immediately available funds) for the amount of cash such holder is entitled to receive under the Arrangement, in accordance with Section 3.1.

Until such time as a Former Shareholder deposits with the Depositary a duly completed Letter of Transmittal, documents, certificates and instruments contemplated by the Letter of Transmittal and such other documents and instruments as the Depositary or the Purchaser reasonably requires, the cash payment to which such Former Shareholder is entitled will in each case be delivered or paid to the Depositary to be held in trust for such Former Shareholder for delivery to the Former Shareholder, without interest upon delivery of the Letter of Transmittal, documents, certificates and instruments contemplated by the Letter of Transmittal and such other documents, certificates and instruments as the Depositary or the Purchaser reasonably requires.

Upon surrender to the Depositary for cancellation of a certificate which immediately prior to the Effective Time represented one or more Common Shares, other than Common Shares held by a Dissenting Shareholder, if applicable, a completed Letter of Transmittal and such additional documents, certificates and instruments as the Depositary or the Purchaser may reasonably require, the holder of such surrendered certificate or the deliverer of such Letter of Transmittal, as applicable, will be entitled to receive in exchange therefor, and the Depositary will deliver to such Former Shareholder following the Effective Time, a cheque (or other form of payment of immediately available funds) for the cash consideration to which such Former Shareholder is entitled to receive in accordance with Article 3 hereof.

Upon surrender to the Depositary for cancellation of a certificate which immediately prior to the Effective Time represented one or more Common Shares held by a Dissenting Shareholder, a completed Letter of Transmittal and such additional documents, certificates and instruments as the Depositary or the Purchaser may reasonably require, the holder of such surrendered certificate or the deliverer of such Letter of Transmittal, as applicable, such Dissenting Shareholder will have a debt claim against the Purchaser in an amount determined in accordance with Article 4.

After the Effective Time and until surrender for cancellation as contemplated by Section 5.1(f) and 5.1(g) hereof, each certificate which immediately prior to the Effective Time represented one or more Common Shares will be deemed at all times to represent only the right to receive in exchange therefor a cheque (or other form of payment of immediately available funds) for any cash consideration to which the holder of such certificate is entitled to receive in accordance with Section 5.1(f) hereof, or, in respect of Common Shares formerly held by a Dissenting Shareholder, a debt claim against the Company in an amount determined in accordance with Article 4.

Amendments to Plan of Arrangement

The Purchaser and the Company may amend, modify and/or supplement this Plan of Arrangement at any time and from time to time prior to the Effective Time, provided that each such amendment, modification and/or supplement must: (i) be set out in writing; (ii) be approved by the Purchaser and the Company; (iii) be filed with the Court and, if made following the Shareholders’ Meeting, approved by the Court; and (iv) be communicated to the Shareholders if and as required by the Court.

Any amendment, modification or supplement to this Plan of Arrangement may be proposed by the Company at any time prior to the Shareholders’ Meeting (provided that the Purchaser shall have consented thereto in writing) with or without any other prior notice or communication (except to the extent required by the Court), and if so proposed and accepted by the Persons voting at the Shareholders’ Meeting (other than as may be required under the Interim Order), shall become part of this Plan of Arrangement for all purposes.

Any amendment, modification or supplement to this Plan of Arrangement that is approved or directed by the Court following the Shareholders’ Meeting shall be effective only if: (i) it is consented to in writing by each of the Purchaser and the Company (in each case, acting reasonably); and (ii) if required by the Court, it is consented to by holders of Common Shares, voting in the manner directed by the Court.

Any amendment, modification or supplement to this Plan of Arrangement may be made following the Effective Date unilaterally by the Purchaser, provided that it concerns a matter which, in the reasonable opinion of the Purchaser, is of an administrative nature required to better give effect to the implementation of this Plan of Arrangement and is not adverse to the economic interest of any former holder of Common Shares, Company Options or Company PSUs and such amendments, modifications or supplements to the Plan of Arrangement need not be filed with Court or communicated to the Shareholders.

The arrangement (the “Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) (the “BCBCA”) involving Merus Labs International Inc. (the “Company”), pursuant to the arrangement agreement (the “Agreement”) between the Company and Norgine B.V. dated May 11, 2017, all as more particularly described and set forth in the management information circular of the Company dated •, 2017 (the “Circular”), accompanying the notice of this meeting (as the Arrangement may be modified or amended in accordance with its terms) is hereby authorized, approved and adopted.

The plan of arrangement, as it has been or may be modified or amended in accordance with the Agreement and its terms, involving the Company (the “Plan of Arrangement”), the full text of which is set out in Appendix “•” to the Circular, is hereby authorized, approved and adopted.

The Agreement and related transactions, the actions of the directors of the Company in approving the Arrangement and the actions of the directors and officers of the Company in executing and delivering the Agreement and any modifications, amendments or supplements thereto and causing the performance by the Company of its obligations thereunder and under the Plan of Arrangement are hereby ratified and approved.

Notwithstanding that this resolution has been passed (and the Arrangement adopted) by the Common Shareholders (as defined in the Agreement) or that the Arrangement has been approved by the Supreme Court of British Columbia (the “Court”), the directors of the Company are hereby authorized and empowered, at their discretion, without further notice to or approval of the Common Shareholders: (i) to amend, modify or supplement the Agreement or the Plan of Arrangement to the extent permitted by the Agreement; and (ii) subject to the terms of the Agreement, not to proceed with the Arrangement and related transactions.

Any officer or director of the Company is hereby authorized and directed for and on behalf of the Company to make an application to the Court for an order approving the Arrangement and to execute, under the corporate seal of the Company or otherwise, and to deliver or cause to be delivered, such documents as are necessary or desirable to give effect to the Arrangement and the Plan of Arrangement in accordance with the Agreement, such determination to be conclusively evidenced by the execution and delivery of such documents.

Any officer or director of the Company is hereby authorized and directed for and on behalf of the Company to execute or cause to be executed and to deliver or cause to be delivered, all such other documents and instruments and to perform or cause to be performed all such other acts and things as, in such person’s opinion, may be necessary or desirable to give full force and effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such other document or instrument or the doing of any other such act or thing.

Organization and Qualification. The Company and each Company Subsidiary is a corporation or other entity duly incorporated or organized, as applicable, validly existing and in good standing under the laws of the jurisdiction of its incorporation, organization or formation, as applicable, and has all requisite power and authority to own, lease and operate its assets and properties and conduct its business as now owned and conducted. The Company has made available to the Purchaser complete and correct copies of the Company’s notice of articles and articles, in each case as amended, and each as so delivered is in full force and effect. The Company and each Company Subsidiary is duly registered to carry on business and is in good standing in each jurisdiction in which the character of its assets and properties, owned, leased, licensed or otherwise held, or the nature of its activities make such qualification, licensing or registration necessary, and has all Authorizations required to own, lease and operate its properties and assets and to conduct its business as now owned and conducted.

Corporate Authorization. The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement (subject to the Company obtaining the approval of the Common Shareholders of the Arrangement Resolution in the manner required by the Interim Order and Law and approval of the Court). The execution, delivery and performance by the Company of its obligations under this Agreement and the consummation of the Arrangement and the other transactions contemplated hereby have been duly authorized by the Board and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement or the consummation of the Arrangement and the other transactions contemplated hereby other than the approval by the Board of the Company Circular, approval by the Common Shareholders in the manner required by the Interim Order and Law and approval by the Court.

Execution and Binding Obligation. This Agreement has been duly executed and delivered by the Company, and constitutes a legal, valid and binding agreement of the Company enforceable against it in accordance with its terms subject only to any limitation under bankruptcy, insolvency or other Laws affecting the enforcement of creditors’ rights generally and the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.

Governmental Authorization. The execution, delivery and performance by the Company of its obligations under this Agreement and the consummation of the Arrangement and the other transactions contemplated hereby do not require any Authorization or other action by or in respect of, or filing with, or notification to, any Governmental Entity by the Company or by any Company Subsidiary other than: (i) the Interim Order and any filings required in in order to obtain, and approvals required by, the Interim Order; (ii) the Final Order, and any filings required in order to obtain the Final Order; (iii) the Regulatory Approvals; (iv) filings with the Securities Authorities; and (v) any Authorizations which, if not obtained, or any other actions by or in respect of, or filings with, or notifications to, any Governmental Entity which, if not taken or made, would not individually or in the aggregate, have a Material Adverse Effect.

Non-Contravention. The execution, delivery and performance by the Company of its obligations under this Agreement and the consummation of the Arrangement and the other transactions contemplated hereby do not and will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition):

contravene, conflict with, or result in any violation or breach of the Company’s Constating Documents or the organizational documents of any Company Subsidiary;

assuming compliance with the matters referred to in Paragraph (4) above, contravene, conflict with or result in a violation or breach of any Law;

except as disclosed in Section 3.1(5)(c) of the Company Disclosure Letter, allow any Person to exercise any rights, require any consent or notice under or other action by any Person, or constitute a default under, or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any material benefit to which the Company or any Company Subsidiary is entitled (including by triggering any rights of first refusal or first offer, change in control provision or other restriction or limitation) under any Material Contract, lease or other instrument, indenture, deed of trust, mortgage, bond or any Authorization to which the Company or any Company Subsidiary is a party or by which the Company or any Company Subsidiary is bound; or

result in the creation or imposition of any Lien upon any of the material properties or material assets of the Company or any Company Subsidiary;

except, in the case of each of clauses (b) through (d), as would not have, individually or in the aggregate, a Material Adverse Effect.

Capitalization.

The authorized capital of the Company consists of an unlimited number of Common Shares, an unlimited number of Company Preferred Shares (10,000 of which are designated as Series A Preferred Shares) (collectively, the “Shares”). As of the close of business on the Business Day prior to the date of this Agreement, there were 117,355,148 Common Shares issued and outstanding and 10,000 Series A Preferred Shares issued and outstanding. All outstanding Shares have been duly authorized and validly issued, are fully paid and non-assessable. All of the Shares issuable under the Company Option Plan, including upon the exercise of Company Options, and the vesting of awards under the PSU Plan have been duly authorized and, upon issuance in accordance with their respective terms, will be validly issued as fully paid and non-assessable Shares and are not and will not be subject to or issued in violation of, any pre-emptive rights. No Shares have been issued and no Company Option or award under the PSU Plan has been granted in violation of any Law or any pre-emptive or similar rights applicable to them.

As of close of business on the Business Day prior to the date of this Agreement there are 6,598,500 Common Shares issuable upon the exercise of outstanding Company Options and 756,701 Common Shares issuable upon the vesting of outstanding awards under the PSU Plan. The Company Option Plan and the issuance of Common Shares under such plan (including pursuant to all outstanding Company Options and awards under the PSU Plan) have been duly authorized by the Board in compliance with Law and the terms of the Company Option Plan and the PSU Plan. Section 3.1(6) of the Company Disclosure Letter sets forth, in respect of each Company Option outstanding as of the close of business on the Business Day prior to the date of this Agreement: (i) the number of Common Shares issuable upon exercise; (ii) the purchase price payable; (iii) the date of grant; (iv) the date of expiry; (v) the name of the registered holder, identifying whether such holder is not an employee of the Company; and (vi) the extent to which such Company Options are vested and are exercisable, identifying whether such vesting or exercise may be accelerated as a result, either alone or together with another event or occurrence, of the Arrangement. Section 3.1(6) of the Company Disclosure Letter sets forth, as of the close of business on the Business Day prior to the date of this Agreement, the number of outstanding Company PSUs, vesting schedule, vested percentage and expiration dates, as applicable, of such Company PSUs.

Except for the conversion rights attached to the Series A Preferred Shares and the rights under the Company Option Plan and the PSU Plan, including outstanding Company Options and awards under the PSU Plan, and there are no issued, outstanding or authorized options, equity-based awards, warrants, calls, conversion, pre-emptive, redemption, repurchase, stock appreciation or other rights, or any other agreements, arrangements, instruments or commitments of any kind that obligate the Company or any Company Subsidiary to, directly or indirectly, issue or sell any securities of the Company or of any Company Subsidiary, or give any Person a right to subscribe for or acquire, any securities of the Company or of any Company Subsidiary.

There are no issued, outstanding or authorized: (i) obligations to repurchase, redeem or otherwise acquire any securities of the Company or of any Company Subsidiary, or qualify securities for public distribution, or, other than as contemplated by this Agreement, with respect to the voting or disposition of any securities of the Company or of any Company Subsidiary; or (ii) notes, bonds, debentures or other evidences of indebtedness or any other agreements, arrangements, instruments or commitments of any kind that give any Person, directly or indirectly, the right to vote with holders of Common Shares on any matter except as required by Law.

All dividends or distributions on securities of the Company that have been declared or authorized have been paid in full.

Shareholders’ and Similar Agreements. Except for the Voting Agreements, neither the Company nor any Company Subsidiary is subject to, or affected by, any unanimous shareholders agreement and is not a party to any shareholder, pooling, voting, or other similar arrangement or agreement relating to the ownership or voting of any of the securities of the Company or of any Company Subsidiary, other than as between the Company and any Company Subsidiary or among Company Subsidiaries, or pursuant to which any Person other than the Company or any Company Subsidiary may have any right or claim in connection with any existing or past equity interest in the Company or in any Company Subsidiary, and as at the date hereof the Company does not have a shareholder rights plan or any similar plan or arrangement that is currently in effect.

Subsidiaries. Section 3.1(8) of the Company Disclosure Letter lists each Company Subsidiary together with the jurisdiction of incorporation of such Company Subsidiary. The Company is, directly or indirectly, the registered and beneficial owner of all of the outstanding shares of each Company Subsidiary, free and clear of any Liens (other than Permitted Liens) and not subject to any restrictions in respect of the sale or assignment of such shares; all such shares or other equity interests so owned by the Company have been validly issued and are fully paid and non- assessable, and no such shares have been issued in violation of any pre-emptive or similar rights. Except for the shares or interests owned by the Company in any Company Subsidiary, the Company does not own, beneficially or of record, any equity interests of any kind in any other Person.

Securities Law Matters.

The Company is a “reporting issuer” under Canadian Securities Laws in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick and ▇▇▇▇▇▇ ▇▇▇▇▇▇ Island.

The Common Shares are listed and posted for trading on the TSX and the NASDAQ and the Company is not in default of any material requirements of any Securities Laws. Except as disclosed in Section 3.1(9) of the Company Disclosure Letter, no delisting, suspension of trading or cease trade or other order or restriction with respect to any securities of the Company is, to the knowledge of the Company, pending, in effect, has been threatened, or is expected to be implemented or undertaken, and, to the knowledge of the Company, the Company is not currently subject to any formal or informal review, enquiry, investigation or other proceeding relating to any such order or restriction. The Company has not filed any confidential material change report (which at the date of this Agreement remains confidential) or any other confidential filings filed to or furnished with, as applicable, any Securities Authority. There are no outstanding or unresolved comments in comments letters from any Securities Authority with respect to the Company’s Public Disclosure Record and, to the knowledge of the Company, neither the Company nor the Company’s Public Disclosure Record is the subject of an ongoing audit, review, comment or investigation by any Securities Authority.

The Company Public Disclosure Record, as filed, complied in all material respects with Law and did not, as of the date filed (or, if amended or superseded by a subsequent filing prior to the date of this Agreement, on the date of such filing), contain any Misrepresentation.

Financial Statements. The Company’s audited consolidated financial statements as at and for the fiscal year ended September 30, 2016 and 2015 (including any of the notes or schedules thereto, the auditor’s report thereon and related management’s discussion and analysis) and the unaudited consolidated interim financial statements as at and for the six months ended March 31, 2017 (including any of the notes or schedules thereto and related management’s discussion and analysis) included in the Company Public Disclosure Record: (i) were prepared in accordance with IFRS; and (ii) present fairly, in all material respects, the financial position of the Company and the Company Subsidiaries as at September 30, 2016 and 2015 and their financial performance and their cash flows for the years then ended in accordance with IFRS (except as may be indicated in the notes to such financial statements). As of the date hereof, the Company does not intend to correct or restate, nor, to the knowledge of the Company is there any basis for any correction or restatement of, any aspect of any of the financial statements of the Company referred to in this Section (10).

Disclosure Controls and Internal Control over Financial Reporting.

The Company has established and maintains a system of disclosure controls and procedures (as such term is defined in NI 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) that is designed to provide reasonable assurance that information required to be disclosed by the Company in its annual and interim filings is: (i) reported within the time periods specified in Securities Laws; and (ii) communicated to the Company’s management in a timely fashion.

The Company has established and maintains a system of internal control over financial reporting (as such term is defined in NI 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) that is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

To the knowledge of the Company, there is no material weakness (as such term is defined in NI 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings) relating to the design, implementation or maintenance of its internal control over financial reporting.

Auditors. The auditors of the Company are independent public accountants as required by Laws.

No Material Undisclosed Liabilities. There are no material liabilities or obligations of the Company or of any Company Subsidiary required to be disclosed in the Company’s financial statements in accordance with IFRS, whether accrued, contingent, absolute, determined, determinable or otherwise, other than liabilities or obligations: (i) disclosed in the audited consolidated financial statements of the Company as at and for the fiscal year ended September 30, 2016 and 2015 (including any notes or schedules thereto and related management’s discussions and analysis); (ii) disclosed in the condensed consolidated interim financial statements of the Company for the six months ended March 31, 2017 and 2016 (including any notes or schedules thereto and related management’s discussions and analysis); (iii) incurred in the Ordinary Course; (iv) that relate to Taxes (which are the subject of Section (29)); or (v) incurred in connection with this Agreement.

Absence of Certain Changes or Events. Since October 1, 2015 to the date of this Agreement, other than the transactions contemplated in this Agreement and as disclosed in the Company Public Disclosure Record, the business of the Company and of each Company Subsidiary has been conducted in the Ordinary Course and there has not occurred a Material Adverse Effect.

Related Party Transactions. Neither the Company nor any Company Subsidiary is indebted to any director, officer, or employee of the Company or any Company Subsidiary (except for amounts due in the Ordinary Course or pursuant to any Law or Contract, such as salaries, bonuses, director's fees or the reimbursement of Ordinary Course expenses). There are no transactions, agreements, arrangements or understandings (other than employment arrangements or other terms of engagement) between the Company or any of the Company Subsidiaries, on the one hand, and any affiliate (including any officer or director, but not including any wholly-owned Subsidiary of the Company) thereof or any shareholder that beneficially owns 5% or more of the Shares, on the other hand.

Compliance with Laws. The Company, each of the Company Subsidiaries is, and has been since October 1, 2015, in compliance in all material respects with Law. Neither the Company nor any of the Company Subsidiaries has engaged in any conduct that could result in criminal liability or disqualification by a Governmental Entity or is under any investigation with respect to, has been charged or threatened to be charged with, or has received notice of, any material violation or potential material violation of any Law or disqualification by a Governmental Entity.

Authorizations and Licenses.

The Company and each Company Subsidiary owns, possesses or has obtained all material Authorizations that are required by Law to be owned, possessed or obtained by it in connection with the operation of the business of the Company and of each Company Subsidiary as presently conducted, or in connection with the ownership, operation or use of the Company Assets.

The Company or the Company Subsidiaries, as applicable, lawfully hold, own or use, and have complied with, all such Authorizations. Each such Authorization is valid and in full force and effect, and is renewable by its terms or in the Ordinary Course.

As of the date hereof, no action, investigation or proceeding is, to the knowledge of the Company, pending in respect of or regarding any material Authorization and none of the Company nor any Company Subsidiary has received notice, whether written or oral, of revocation, non-renewal or material amendments of any such Authorization, or of the intention of any Person to revoke, refuse to renew or materially amend any such Authorization.

Material Contracts.

Section 3.1(18)(a) of the Company Disclosure Letter sets out a complete and accurate list of all Material Contracts. True and complete copies of the Material Contracts have been made available to the Purchaser.

Each Material Contract is legal, valid, binding and in full force and effect and is enforceable by the Company or a Company Subsidiary, as applicable, in accordance with its terms (subject to bankruptcy, insolvency and other Laws affecting creditors’ rights generally, and to general principles of equity).

The Company and each Company Subsidiary has performed in all material respects all respective obligations required to be performed by them to date under the Material Contracts and, to the knowledge of the Company, neither the Company nor any Company Subsidiary is in material breach or default under any Material Contract, nor does the Company have knowledge of any condition that with the passage of time or the giving of notice or both would result in such a breach or default.

As of the Business Day prior to the date of this Agreement, neither the Company nor any Company Subsidiary has received any notice (whether written or oral), that any party to a Material Contract intends to cancel, terminate or otherwise modify or not renew its relationship with the Company or any of its Subsidiaries, and, to the knowledge of the Company, no such action has been threatened.

Title to Company Assets. The Company and the Company Subsidiaries have valid, good and marketable title to all material Company Assets which the Company or any Company Subsidiary purports to own, free and clear of all Liens (other than Permitted Liens). The Company and the Company Subsidiaries, as lessees, have the right under valid and subsisting leases to use, possess and control all material Company Assets leased to the Company or any Company Subsidiary as used, possessed and controlled by the Company or the Company Subsidiaries, as applicable.

Leased Real Property.

Section 3.1(20) of the Company Disclosure Letter contains a true, complete and correct list, as of the date of this Agreement, of all of the existing leases, subleases, licenses or other agreements pursuant to which the Company or any of its Subsidiaries uses or occupies, or has the right to use or occupy, now or in the future, any real property (such property, the “Leased Real Property”) and sets out: (i) the municipal address and applicable unit or premises leased; and (ii) the date of the applicable lease and any amendments to it (such documents, collectively, the “Real Property Lease”).

The Real Property Lease is valid and subsisting, in full force and effect and the Company and each Company Subsidiary, as the case may be, is entitled to the full benefit and advantage of each Real Property Lease in accordance with its terms.

The Company and each Company Subsidiary is in good standing under all, and is not in material default under any, and to the knowledge of the Company and each Company Subsidiary there is no existing condition, circumstance or matter which constitutes or which with the passage of time or the giving of notice, would constitute a default in respect of the Real Property Lease or any material Company Assets.

All leasehold improvements undertaken by the Company or the Company Subsidiaries in respect of the Leased Real Property have been approved by the landlord under the Real Property Lease and, to the knowledge of the Company, do not include any non-standard improvements.

Regulatory Matters.

The Company and each Company Subsidiary (i) is, and since October 1, 2015, has been, in compliance in all material respects with all Drug Regulatory Laws and (ii) holds all Regulatory Approvals and Authorizations that are necessary for the conduct of the business as presently conducted, with the product Authorizations set out in Section (21)(a) of the Company Disclosure Letter. Each such Regulatory Approval and Authorization is valid, subsisting and in good standing, the Company and each Company Subsidiary is not in default or breach of any such Regulatory Approval and Authorization and, to the knowledge of the Company, no proceeding is pending or threatened to revoke, cancel, suspend, not renew or limit any such Regulatory Approval or Authorization. The Company and each Company Subsidiary has, in all material respects, fulfilled and performed, and is performing, all of its obligations with respect to the Regulatory Approvals and Authorizations, and no event has occurred which allows, or after notice or lapse of time would allow, revocation, suspension or termination thereof or results in any other impairment of the rights of the holder of any such Regulatory Approvals and Authorizations.

All products of the Company and the Company Subsidiaries have been developed, tested, manufactured, produced, fabricated, processed, handled, possessed, packaged, labelled, stored, transported, advertised, promoted, marketed, imported, exported, sold or distributed in accordance with applicable Drug Regulatory Laws and all requirements of applicable Governmental Entities in all material respects.

All reports, applications, documents, claims, permits and notifications required to be filed, maintained or furnished with each relevant Governmental Entity have been duly filed, maintained or furnished by the Company or the Company Subsidiaries, including all adverse event reporting. Without limiting the foregoing, all reports and materials have been duly filed with all Governmental Entities responsible for regulating the pricing of the Company or the Company Subsidiaries products, and to the knowledge of the Company, the Company and the Company Subsidiaries are not under investigation by a Governmental Entity with respect to the sales of products in violation of any pricing restrictions, excessive pricing of products or the provision of unlawful incentives, inducements or rebates.

Each of the Company and the Company Subsidiaries has not voluntarily or involuntarily initiated, conducted or issued, or caused to be initiated, conducted or issued, nor is there currently under consideration by the Company, the Company Subsidiaries or any Governmental Entity, any recall, market withdrawal or replacement, field alerts, field corrections, safety alert, warning or other notice of action related to an alleged misbranding, adulteration, lack of safety, efficacy or regulatory compliance of any of the Company or Company Subsidiary’s products or any other form of product retrieval from the marketplace in respect of any such products or any revocation or suspension of a Regulatory Approval or Authorization with respect to such products including, without limitation, the loss or suspension of the listing of any products on federal or provincial formulary.

As of the date hereof, there are no facts or circumstances relating to the Business, products or Regulatory Authorizations that would reasonably be expected to result in (A) the recall, market withdrawal or replacement of any Product sold or intended to be sold by the Company or the Subsidiaries, (B) a change in the marketing classification or a material change in the labelling of any products, or (C) a termination or suspension of the Regulatory Authorizations for such products.

No claims related to product liability have been initiated against the Company or the Company Subsidiaries and, to the knowledge of Company, no such claims have been threatened or filed against the Company or the Company Subsidiaries relating to any of their products. There is no judgment, order, injunction, decision or award outstanding against the Company or the Company Subsidiaries relating to any such claim on account of any of the Company’s or the Company Subsidiaries’ products.

Intellectual Property

All Intellectual Property that is material to the operation of the business (other than off- the-shelf software licences) (i) is owned by the Company, or (ii) is licensed to the Company pursuant to an agreement that is listed on Section 3.1(18)(a) of the Company Disclosure Letter (the “Company IP”).

Section 3.1(22) of the Company Disclosure Letter contains a true and complete list of all Intellectual Property that is owned by the Company or the Company Subsidiaries and subject to an application or registration (by name, owner and, where applicable, registration or application number and jurisdiction) (the “Registered IP”). All of the registrations and applications for registration of the Registered IP are valid and subsisting, in good standing and are recorded in the name of the Company or the Company Subsidiaries.

All Company IP is (i) valid, subsisting and enforceable, and (ii) to the knowledge of the Company, not subject to any outstanding order, judgment or decree adversely affecting the use of or the rights to such Company IP by the Company or the Company Subsidiaries.

As at the date of this Agreement, neither the Company nor any of the Company Subsidiaries is a party to any Proceedings directed or related to Company IP and no Proceeding directed or related to Intellectual Property is threatened in writing against the Company or the Company Subsidiaries (A) alleging that the Company or the Company Subsidiaries have infringed, misappropriated or otherwise violated the Intellectual Property rights of any Person or (B) challenging or seeking to deny, revoke or limit the rights of the Company or the Company Subsidiaries in any Company IP. To the knowledge of the Company, no Person is infringing, misappropriating or otherwise violating any Company IP.

The Company and each Company Subsidiary have taken commercially reasonable measures to protect and maintain the secrecy and security of data and non-public information that is owned by the Company or any Company Subsidiary or that any of them (or a third Person on behalf of any of them) collects, stores, uses, maintains or transmits and to prevent unauthorized access to, use of, or disclosure of such data or non- public information by any other Person.

All patents held by the Company or a Company Subsidiary that relate to a product (including in relation to a use, dosage form or formulation of a product), to the extent that such patents are eligible for listing in accordance with the requirements of the Patent Act and Patented Medicines (Notice of Compliance) Regulations, have been duly and timely submitted to Health Canada for listing on Health Canada’s patent register.

Litigation. As at the date of this Agreement, except any inquiry, investigation or proceeding solely related to satisfying or obtaining the Regulatory Approvals, there are no material claims, actions, suits, arbitrations, inquiries, investigations or proceedings in effect or ongoing, or to the knowledge of the Company, pending or threatened against the Company or any Company Subsidiary, or affecting any of their respective properties or assets, by or before any Governmental Entity that, if determined adverse to the interests of the Company or the Company Subsidiaries, would have, individually or in the aggregate, a Material Adverse Effect or would be reasonably expected to prevent or materially delay the consummation of the Arrangement or the transactions contemplated hereby, nor, to the knowledge of the Company, are there any events or circumstances which could reasonably be expected to give rise to any such claim, action, suit, arbitration, inquiry, investigation or proceeding. As at the date of this Agreement, there is no bankruptcy, liquidation, winding-up or other similar proceeding pending, in progress or to the knowledge of the Company threatened against or relating to the Company or any Company Subsidiary before any Governmental Entity. As at the date of this Agreement, neither the Company nor any Company Subsidiary, nor any of their respective properties or assets, is subject to any outstanding judgment, order, writ, injunction or decree that would have or would be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect or that would be reasonably expected to prevent or materially delay the consummation of the Arrangement or the transactions contemplated hereby.

Environmental Matters.

The Company and each Company Subsidiary is in compliance, in all material respects, with all Environmental Laws.

The Company and the Company Subsidiaries are in possession of, and in compliance with, all Authorizations required by Environmental Laws that are required to own, lease, develop and operate the Company Assets and to conduct their respective businesses, as now conducted, except as would not, individually or in the aggregate, have a Material Adverse Effect.

Except as would not, individually or in the aggregate, have a Material Adverse Effect: (i) none of the Company nor any Company Subsidiary have Released any Hazardous Substance, and (ii) to the knowledge of the Company, no other Person has Released a Hazardous Substance (in each case except in compliance with Environmental Laws) on, at, in, under or from any of the immovable properties, any real properties, or any lands comprising or connected with the Company Assets.

To the knowledge of the Company, as at the date of this Agreement, there are no pending or threatened claims against the Company or any Company Subsidiary arising out of any Environmental Laws, except as would not, individually or in the aggregate, have a Material Adverse Effect.

As at the date of this Agreement, the Company is not aware of, nor has it received: (i) any order or directive which relates to environmental matters that would have a Material Adverse Effect; or (ii) any demand or notice with respect to the material breach of any Environmental Law.

Employees.

Section 3.1(25)(a) of the Company Disclosure Letter lists all Company Employees and independent contractors or consultants who are receiving remuneration for work or services provided to the Company or any Company Subsidiary as of the date of this Agreement and his or her position, status (full-time or part-time), whether subject to a written employment agreement, length of service, location, base salary, bonus arrangements, commissions and consulting fees as of April 1, 2017. Except as set out in Section 3.1(25)(a) of the Company Disclosure Letter, no Company Employee is on short term or long-term disability leave, a statutory leave of absence, an unpaid leave of absence or receiving benefits pursuant to applicable workers’ compensation legislation. Written employment contracts of all Company Employees and current independent contractors and consultants have been made available to the Purchaser.

Section 3.1(25)(b) of the Company Disclosure Letter lists all Company Employees that have any agreement as to length of notice or severance payment required to terminate his or her employment, other than such as results by Law from the employment of an employee without an agreement as to notice or severance.

To the knowledge of the Company, neither the Company nor any Company Subsidiary has received any notice from any Governmental Entity disputing the classification of its independent contractors.

The Company is in compliance in all material respects, with all terms and conditions of employment and all Law respecting employment, including pay equity, wages, hours of work, overtime, human rights and occupational health and safety, and there are no outstanding claims, complaints, investigations, grievances, arbitrations or orders under any such Laws related to Company Employees or former Company Employees and to the knowledge of the Company there is no basis for such claim.

All amounts due or accrued for all salary, wages, bonuses, commissions, vacation with pay, sick days with pay, termination and severance pay and benefits under Employee Plans and other similar accruals have either been paid or are accurately reflected in the books and/or records of the Company or of the applicable Company Subsidiary.

There are no outstanding assessments, penalties, fines, liens, charges, surcharges, or other amounts due or owing pursuant to any workplace safety and insurance legislation and neither the Company nor any Company Subsidiary has been reassessed in any respect under such legislation since October 1, 2015 and, to the knowledge of the Company, no audit of the Company or any Company Subsidiary is currently being performed pursuant to any applicable workplace safety and insurance legislation. As of the date of this Agreement, there are no claims or, to the knowledge of the Company, potential claims pursuant to any workplace safety and insurance legislation which are reasonably likely to materially adversely affect the accident cost experience in respect of the Company or any Company Subsidiary.

To the knowledge of the Company, there are no charges pending with respect to the Company or any Company Subsidiary under OHSL. The Company and each Company Subsidiary have complied in all material respects with the terms and conditions of OHSL, as well as any orders issued under OHSL and there are no appeals of any orders under OHSL currently outstanding.

Except as expressly contemplated in this Agreement, neither the execution and delivery of this Agreement (alone or in connection with additional or subsequent events) or any termination of employment or service in connection therewith will (i) result in any payment, bonus, severance, fee, remuneration, benefit or other compensation to any Company Employee (other than salaries, wages, fees or bonuses paid or payable to Company Employees in the ordinary course of business in accordance with current compensation levels and practices), (ii) result in any forgiveness of indebtedness to any Company Employee, or (iii) increase any payments or benefits otherwise payable or to be provided by the Company or any Company Subsidiary to a Company Employee or under an Employee Plan.

Collective Agreements.

Neither the Company nor any Company Subsidiary is a party to, nor is engaged in any labour negotiations with respect to any Collective Agreement, any actual or, to the knowledge of the Company, threatened application for certification or bargaining rights or letter of understanding, with respect to any current or former Company Employee. Neither the Company nor any Company Subsidiary is currently subject to any union organization effort, nor to the knowledge of the Company is a union organizing effort involving any Company Employees threatened or pending. No trade union, council of trade unions, employee bargaining agency or affiliated bargaining agent holds bargaining rights with respect to any aspect of the Company Employees by way of certification, interim certification, voluntary recognition, or succession rights of any employees.

To the knowledge of the Company, there is no labour strike, dispute, lock-out work slowdown or stoppage pending or involving or threatened against the Company or any Company Subsidiary, nor has there been any such labour strike, dispute, lock-out, work slowdown or stoppage within the last three (3) years.

Neither the Company nor any Company Subsidiary has or is engaged in any unfair labour practice nor is the Company aware of any pending or threatened unfair labour practice complaint, grievance or arbitration proceeding against the Company or any Company Subsidiary.

To the knowledge of the Company, as at the date of this Agreement, no trade union has applied to have the Company or a Subsidiary declared a related successor, or common or related employer pursuant to the applicable labour relations legislation in any jurisdiction in which the Company or any Company Subsidiary carries on business.

Employee Plans.

Section 3.1(27)(a) of the Company Disclosure Letter lists all material Employee Plans. The Company has made available to the Purchaser true, correct and complete copies of all such Employee Plans as amended, together with all related documentation.

Each Employee Plan is and has been established, registered, qualified, funded and administered in accordance with Law and in accordance with its terms. To the knowledge of the Company, no fact or circumstance exists which could adversely affect the registered status of any Employee Plan. To the knowledge of the Company, the Company has not breached any fiduciary obligation with respect to the administration or investment of any Employee Plan.

All contributions, premiums or taxes required to be made or paid by the Company or any Company Subsidiary, as the case may be, under the terms of each Employee Plan or by Law have been made in a timely fashion.

No Employee Plan is subject to any investigation, examination or other proceeding, action or claim initiated by any Governmental Entity, or by any other party (other than routine claims for benefits) and, to the knowledge of the Company, there exists no state of facts which after notice or lapse of time or both would reasonably be expected to give rise to any such investigation, examination or other proceeding, action or claim or to affect the registration or qualification of any Employee Plan required to be registered or qualified.

No Employee Plan is or is intended to be a “registered pension plan”, a “deferred profit sharing plan”, a “retirement compensation arrangement”, a “registered retirement savings plan”, a “pooled registered pension plan” or a “tax-free savings account” as such terms are defined in the Tax Act.

None of the Employee Plans provides post-retirement or post-employment benefits to or in respect of current or former Company Employees.

Insurance.

The Company and each Company Subsidiary is insured by reputable third party insurers with reasonable and prudent policies appropriate for the size and nature of the business of the Company and the Company Subsidiaries. To the knowledge of the Company, each such insurance policy currently in effect that insures the physical properties, business, operations and assets of the Company and its Subsidiaries is valid and binding and in full force and effect. To the knowledge of the Company, as at the date of this Agreement, there is no material claim pending under any such insurance policy that has been denied, rejected, questioned or disputed by any insurer or as to which any insurer has made any reservation of rights or refused to cover any material portion of such claims.

Taxes.

The Company and each Company Subsidiary has duly and timely filed all material Tax Returns required to be filed by them prior to the date hereof and all such Tax Returns are complete and correct in all material respects, except as would not, individually or in the aggregate, have a Material Adverse Effect.

The Company and each Company Subsidiary has paid on a timely basis all Taxes which are due and payable by them on or before the date hereof, other than those which are being or have been contested in good faith and in respect of which adequate reserves have been provided in the most recently published consolidated financial statements of the Company. The Company has provided adequate accruals in accordance with IFRS in the most recently published consolidated financial statements of the Company for any Taxes of the Company and each Company Subsidiary for the period covered by such financial statements that have not been paid whether or not shown as being due on any Tax Returns. Since such publication date, no material liability in respect of Taxes not reflected in such statements or otherwise provided for has been incurred or accrued other than in the Ordinary Course.

No material deficiencies, litigation or proposed adjustments have been asserted with respect to Taxes of the Company or any Company Subsidiary, and neither the Company nor any Company Subsidiary is a party to any material action or proceeding for assessment or collection of Taxes and no such event has been asserted against the Company or any Company Subsidiary or any of their respective assets.

To the knowledge of the Company, no claim has been made by any Government Entity that the Company or any Company Subsidiary is required to file Tax Returns or pay any material Taxes in any jurisdiction where it does not do so.

There are no Liens (other than Permitted Liens) with respect to Taxes upon any of the assets of the Company or any Company Subsidiary.

The Company and each Company Subsidiary has withheld, charged or collected all material amounts required to be withheld, charged or collected by it on account of Taxes and has remitted all such amounts to the appropriate Governmental Entity when required by Law to do so.

Other than waivers that were filed solely for the purpose of permitting the Company to claim deductions in order to reduce Taxes arising from adjustments to income arising from assessments or reassessments of Tax for prior taxation years and for which the Company has filed objections or appeals in respect of such amendments or reassessments (the “Protective Waivers”), there are no outstanding agreements extending or waiving the statutory period of limitations applicable to any claim for, or the period for the collection or assessment or reassessment of Taxes due from the Company or any Company Subsidiary for any taxable period and no request for any such waiver or extension is currently pending. For greater certainty, no Protective Waiver allows the relevant Governmental Entity to assess or reassess additional Tax in respect of the taxation year to which the Protective Waiver relates.

Except as disclosed to Purchaser prior to the date hereof, neither the Company nor any Company Subsidiary has ever directly or indirectly transferred any material amount of property to, supplied any material amount of services to, or acquired any material property or services from, a Person with whom it was not dealing at arm's length (for the purposes of the Tax Act) for consideration other than consideration equal to the fair market value of the property or services at the time of the transfer, supply or acquisition of the property or services, nor has the Company or any Company Subsidiary been deemed to have done so for purposes of the Tax Act.

There are no circumstances existing which could result in the application to the Company or any Company Subsidiary of, section 78 or sections 80 to 80.04 of the Tax Act or any analogous provision of any comparable Law of any province or territory of Canada.

Board Approval. As of the date of this Agreement, the Board, after consultation with its legal advisors and the Financial Advisors, has: (i) determined that the Arrangement is fair to Common Shareholders and that the Arrangement is in the best interests of the Company; (ii) resolved to recommend that the Common Shareholders vote in favour of the Arrangement Resolution; and (iii) authorized the entering into of this Agreement and the performance by the Company of its obligations under this Agreement, and no action has been taken to amend, or supersede, such determinations, resolutions or authorizations.

Opinion of Financial Advisors. As at the date hereof, the Board has received the Fairness Opinions.

No Options, etc. to Purchase Assets. No Person has any written or oral agreement, option, understanding or commitment, or any right or privilege capable of becoming such for the purchase or other acquisition from the Company or any Company Subsidiary of any of the Company Assets, other than Company Assets which are obsolete or inventory to be sold in the Ordinary Course.

Brokers. Except for the engagement letters between the Company and the Financial Advisor(s) and the fees payable under or in connection with such engagements, no investment banker, broker, finder, financial adviser or other intermediary has been retained by or is authorized to act on behalf of the Company or any Company Subsidiary or is entitled to any fee, commission or other payment from the Company or any Company Subsidiary in connection with this Agreement or any other transaction contemplated by this Agreement. A true and complete copy of the engagement letters between the Company and the Financial Advisors have been disclosed to the Purchaser and the Company has made true and complete disclosure to the Purchaser of all fees, commissions or other payments that may be incurred pursuant to such engagement or that may otherwise be payable to the Financial Advisors.

Organization and Qualification. The Purchaser is a corporation duly incorporated and validly existing under the Laws of the jurisdiction of its incorporation and has all requisite power and authority to own, lease and operate its assets and properties and conduct its business as now owned and conducted.

Corporate Authorization. The Purchaser has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and to complete the transactions contemplated by this Agreement. The execution, delivery and performance by the Purchaser of its obligations under this Agreement and the consummation of the Arrangement and the other transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of the Purchaser and no other corporate proceedings on the part of the Purchaser are necessary to authorize the execution and delivery by each of them of this Agreement or the consummation of the Arrangement and the other transactions contemplated hereby.

Execution and Binding Obligation. This Agreement has been duly executed and delivered by the Purchaser and constitutes a legal, valid and binding agreement of the Purchaser enforceable against the Purchaser in accordance with its terms subject only to any limitation under bankruptcy, insolvency or other Laws affecting the enforcement of creditors’ rights generally and the discretion that a court may exercise in the granting of equitable remedies such as specific performance and injunction.

Governmental Authorization. The execution, delivery and performance by the Purchaser of its obligations under this Agreement and the consummation by the Purchaser of the Arrangement and the transactions contemplated hereby do not require any Authorization or other action by or in respect of, or filing with, or notification to, any Governmental Entity by the Purchaser other than: (i) the Interim Order and any filings required in order to obtain, and any approvals required by, the Interim Order; (ii) the Final Order; (iii) the Regulatory Approvals identified in accordance with this Agreement; and (iv) any Authorizations which, if not obtained, or any other actions by or in respect of, or filings with, or notifications to, any Governmental Entity which, if not taken or made, would not be reasonably expected to, individually or in the aggregate, prevent or materially impede the ability of the Purchaser to consummate the Arrangement and the transactions contemplated hereby.

Non-Contravention. The execution, delivery and performance by the Purchaser of its obligations under this Agreement and the consummation of the Arrangement and the transactions contemplated hereby do not and will not (or would not with the giving of notice, the lapse of time or the happening of any other event or condition):

contravene, conflict with, or result in any violation or breach of the organizational documents of the Purchaser; or

assuming compliance with the matters referred to in Paragraph (4) above, contravene, conflict with or result in a violation or breach of any Law except as would not, individually or in the aggregate, materially impede the ability of the Purchaser to consummate the Arrangement and the transactions contemplated hereby.

Litigation. There are no claims, actions, suits, arbitrations, inquiries, investigations or proceedings pending, or, to the knowledge of the Purchaser, threatened, against or involving the Purchaser or any of its affiliates by or before any Governmental Entity nor are the Purchaser or any of its affiliates subject to any outstanding judgment, order, writ, injunction or decree that, either individually or in the aggregate, is reasonably likely to prevent or materially delay the consummation of the of the transactions contemplated by this Agreement.

Financing. The Purchaser will have at the Effective Time sufficient funds available to satisfy the aggregate consideration payable by the Purchaser pursuant to the Arrangement in accordance with the terms of this Agreement and the Arrangement, and to satisfy all other obligations payable by the Purchaser pursuant to this Agreement and the Arrangement. The Purchaser delivered to the Company a complete and accurate copy of the facilities agreement and intercreditor agreement, and any relevant fee letters (with only the fee and any other economic provisions redacted, none of which would permit the Lenders (as defined below) to reduce the amount or availability of the Financing except as permitted by Section 4.5) from the financial institutions (the “Lenders”) identified therein (the “Financing Documents”) pursuant to which such financial institutions have committed to provide, subject to the terms and conditions therein, debt financing in the amounts set forth therein for the purpose of funding the Arrangement and the transactions contemplated by this Agreement (being collectively referred to as the “Financing”). The Financing Documents have not been amended or modified and the Lenders’ respective commitments contained in such letters and agreements have not been withdrawn, terminated, rescinded or reduced (except as permitted by Section 4.5) in any respect by the Purchaser or, to the knowledge of the Purchaser, the Lenders, as applicable. Assuming the Financing is funded pursuant to the Financing Documents, the net proceeds of the Financing, together with cash held by the Purchaser, will, in the aggregate be sufficient to enable the Purchaser to fund the Aggregate Consideration and make all other payments of any fees and expenses required to be paid in connection with the Arrangement and the Financing, and to pay amounts related to refinancing of any outstanding indebtedness of the Company contemplated by the Financing Documents. Assuming accuracy of the representations and warranties of the Company hereunder, as of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would constitute a default or breach on the part of the Purchaser under the Financing Documents or, to the knowledge of the Purchaser, any other parties thereto, or a failure of any condition to the Financing or otherwise result in any portion of the Financing contemplated thereby to be unavailable on the Effective Date. Assuming satisfaction of the conditions set forth in Section 6.1 and Section 6.2 of the Agreement, the Purchaser has no reason to expect that any of the conditions of the Purchaser to the Financing will fail to timely be satisfied or that the full amount of the Financing will not be available on the Effective Date. There are no conditions precedent related to the funding of the full amount of the Financing, other than as expressly set forth in or contemplated by the Financing Documents. The Purchaser or its affiliates have paid in full any and all commitment fees or other fees required to be paid pursuant to the terms the Financing Documents on or before the date of this Agreement, and will pay in full any such amounts due on or prior to the Effective Time. There are no side letters or other agreements, contracts or arrangements to which the Purchaser is a party which are related to the funding of the full amount of the Financing other than as expressly set forth in or contemplated by the Financing Documents. Notwithstanding anything to the contrary contained herein, each Party agrees that a breach of this representation and warranty will not result in the failure of a condition precedent hereunder, if (notwithstanding such breach) (i) the Purchaser is willing and able to consummate the Arrangement on the Effective Date, and (ii) has funds sufficient to consummate the transactions contemplated hereby at the Effective Time.

(8)

WTO Investor. The Purchaser is a “WTO Investor” as defined by Section 14.1(6) of the Investment Canada Act.

Finders’ Fees. Other than the Royal Bank of Canada, there is no investment banker, broker, finder, financial advisor or other intermediary that has been retained by or is authorized to act on behalf of the Purchaser or any of its affiliates who might be entitled to any fee, commission or other payment in connection with this Agreement from the Company or any of the Company Subsidiaries upon consummation of the transactions contemplated by this Agreement.

Security Ownership. Neither the Purchaser nor any of its affiliates or any other Person acting jointly or in concert with any of them, beneficially owns or control, or will prior to the Effective Date beneficially own or control, any Common Shares, Company Preferred Shares or any securities that are convertible into or exchangeable or exercisable for such shares.

Ownership of Purchaser. ▇▇▇▇▇ ▇▇▇▇▇ and his Related Parties (as defined in the Financing Documents) together hold beneficially, directly or indirectly, issued share capital of the Purchaser having the right to cast more than 50% of the votes capable of being cast in a general meeting of the Purchaser or the right to determine the composition of the majority of the board of directors or equivalent body of the Purchaser.